

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Study protocol for a double blinded, randomised controlled trial to assess the effectiveness of endolymphatic duct blockage versus endolymphatic sac decompression in patients with intractable Ménière's disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054514
Article Type:	Protocol
Date Submitted by the Author:	16-Jun-2021
Complete List of Authors:	Schenck, Annejet; Haga Hospital, Otorhinolaryngology Kruyt, Josephina; Medical Centre Haaglanden, Otorhinolaryngology van Benthem, Peter Paul; Leiden University Medical Centre, Departement of Otorhinolaryngology Cannegieter, Suzanne; Leiden University Medical Centre, Leiden, Department of Thrombosis and Hemostasis; Leiden University Medical Centre, Department of Clinical Epidemiology van den Hout, Wilbert; University Medical Center Leiden, Medical Decisionmaking Böhringer, Stefan; Leiden University Medical Center, Biomedical Data Sciences Hammer, Sebastiaan; Haga Hospital, Department of Radiology Hombergen, Susan; Haga Hospital, Department of Physiotherapy Blom, H.M.; Haga Hospital, Department of Otorhinolaryngology
Keywords:	Adult otolaryngology < OTOLARYNGOLOGY, Audiology < OTOLARYNGOLOGY, Head & neck surgery < OTOLARYNGOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **TITLE PAGE**

4
5 2 **Title**

6
7 3 Study protocol for a double blinded, randomised controlled trial to assess the effectiveness of
8 4 endolymphatic duct blockage versus endolymphatic sac decompression in patients with
9 5 intractable Ménière's disease.

10 6 Version 5, May 20th 2021
11
12
13
14
15
16

17 8 **Authors**

18 9 A.A. Schenck 1, 2, *

19
20
21 10 J.M. Kruyt 3

22
23 11 P.P. van Benthem 2

24
25 12 S.C. Cannegieter 4

26
27 13 W.B. Van den Hout 5

28
29 14 S. Boehringer 6

30
31 15 S. Hammer 7

32
33 16 S.P.M. Hombergen 8

34
35 17 H.M. Blom 1, 2, 9
36
37
38
39
40

41 19 1 Department of Otorhinolaryngology, HagaHospital, the Hague, the Netherlands

42
43 20 2 Department of Otorhinolaryngology, Leiden University Medica Centre, Leiden, the
44 21 Netherlands

45
46
47 22 3 Department of Otorhinolaryngology, Haaglanden Medical Center, the Hague, the
48 23 Netherlands

49
50
51 24 4 Department of Clinical Epidemiology, Leiden University Medica Centre, Leiden, the
52 25 Netherlands

53
54
55 26 5 Medical Decision Making & Quality of Care, Leiden University Medica Centre, Leiden, the
56 27 Netherlands

57
58 28 6 Department of Statistics, Leiden University Medica Centre, Leiden, the Netherlands
59
60

1
2
3 29 7 Department of Radiology, HagaHospital, the Hague, the Netherlands
4
5 30 8 Department of Physiotherapy, HagaHospital, the Hague, the Netherlands
6
7 31 9 Department of Otorhinolaryngology, Antwerp University Hospital, Belgium
8
9

10 32

11 33 * Corresponding author

12
13 34 Adress: Els Borst-Eilersplein 275, postbox 40551, 2545 AA, the Hague, the Netherlands

14
15 35 Email: j.schenck@hagaziekenhuis.nl, telephone: 0031 70 210 2602, fax: 0031 70 210 4023

16
17 36

18
19
20 37 **Keywords**

21 38 Meniere's disease

22 39 Endolymphatic duct blockage

23 40 Vertigo

24 41 Endolymphatic hydrops

25
26 42

27
28 43 **Word Count:** 4024

44 **Abstract**

45 *Introduction.* Outcomes of surgery for Meniere's disease (MD) remain discordant. Recently, a
46 new surgical procedure in which the endolymphatic duct is clipped, was proposed. To date,
47 only one prospective trial assessing this technique was published, yielding promising results.
48 The present protocol describes a prospective, double blinded, randomized controlled trial
49 that will be carried out to assess effectiveness of this surgical intervention.

50
51 *Methods.* Eighty-four patients with intractable Meniere's disease will be recruited from 13
52 hospitals in the Netherlands. Intraoperatively, randomization will determine whether
53 endolymphatic duct blockage (EDB) or endolymphatic sac decompression (ESD) will be
54 performed. Randomization will be 1:1 stratified for gender and duration of MD (recent onset
55 versus mature MD). All participants receive vestibular rehabilitation after surgery. Patients
56 are followed up during one year after surgery. Follow up visits will take place at 1 week, 3
57 months, 6 months and 12 months after surgery. The main study endpoint is proportion of
58 patients who are free of vertigo spells at 12 months post-operatively. Secondary parameters
59 include cumulative number of vertigo bouts, co-intervention, tinnitus, hearing, quality of life,
60 cost-effectiveness and a budget impact analysis. Total duration of the study is 4 years.

61
62 *Analysis.* The primary analysis will follow the intention-to-treat principle. For the primary
63 outcome, a chi-square test will be performed. Secondary outcomes will be analyzed using a
64 linear mixed model (EDB vs decompression group) at the different time measurement point.

65
66 *Ethics and dissemination.* This study was reviewed and approved by a board of specialists
67 before funding was obtained, as well as by the Medical Research Ethics Committee Leiden
68 The Hague Delft and the boards of all participating centres. Results of this study will be
69 published in international peer-reviewed scientific journals and will be presented on
70 (inter)national scientific conferences and meetings.

71 **Strengths and limitations of this study**

- 72 - In this study, both patient and clinician will remain blinded throughout the follow up period to
73 minimize bias
- 74 - The prospective design diminishes the risk of missing data and enables measurements of
75 many parameters that are relevant for this disease
- 76 - The number of participating centers ensures a quick dissemination of the results
- 77 - The absence of comparison to a placebo intervention and a study arm with patients who do
78 not undergo any intervention is a limitation of this trial

79 Introduction

80 Ménière's disease (MD) is an incapacitating disease of recurrent vertigo attacks,
81 accompanied by hearing loss, tinnitus and/or aural fullness. Between the attacks of vertigo
82 intervals of days, weeks or even months may occur [1, 2]. The natural course of MD has
83 been studied and it has been found that the attacks of vertigo become less severe and
84 disappear after two years in 60% and after eight years in 80% of patients [3-6]. In the end
85 phase of the disease patients without vertigo attacks may still suffer from lasting hearing loss
86 and tinnitus and chronic instability caused by hypofunction of the labyrinth.

87 The disease is of idiopathic origin, but is associated with endolymphatic hydrops in the inner
88 ear [7]. Visualization of the hydrops became possible with the introduction of delayed post-
89 contrast high resolution MR imaging [8-11]. Hydrops is associated with duration of MD and
90 saccular hydrops is associated with sensorineural hearing loss [12]. Perilymphatic signal
91 intensity is a surrogate marker for impaired blood-labyrinth permeability. Signal intensity
92 (without) hydrops is markedly increased in the acute phase of labyrinthitis and is increased in
93 patients with MD [13].

94 Few articles have been published on the epidemiology of MD. Great variation exists in the
95 published reports of the prevalence of MD, ranging from 34.5 to 218 cases per 100,000 [14-
96 17]. The difference in prevalence might be due to the wide variations in definitions of MD.
97 There seems to be a slight female preponderance, with up to 1.3 times more women affected
98 than men. The disease is more common in adults in their fourth and fifth decade of life [5, 6,
99 17].

100 *Treatment options*

101 The treatment of MD both in primary and secondary care setting is focused on the reduction
102 of the frequency and intensity of vertigo attacks. Current treatments have either proven to be
103 ineffective (Betahistin [18]), only have a temporary effect (intratympanic dexamethasone
104 injections [19], or methylprednisolone [20]), or destroy the labyrinth function (intratympanic
105 gentamicin, labyrinthectomy, selective neurectomy [2, 21, 22]). Surgical destruction of the
106 labyrinth reduces the episodes of attacks but causes loss of balance as well, due to one
107 dysfunctional labyrinth. Moreover, permanent sensorineural hearing loss is reported after this
108 treatment.

109 Recently, an international guideline for the diagnostic work-up and treatment of MD was
110 published [23]. It recommends step-up treatment, starting with education of patients and
111 discussing diuretics/betahistine. Intratympanic administration of corticosteroids is considered
112 optional if patients do not respond to more conservative therapy. The last non-ablative option
113 that can be considered, is endolymphatic sac decompression. Endolymphatic sac

1
2
3 114 decompression (ESD) consists of a mastoidectomy and, after identification of the
4 115 endolymphatic sac, wide decompression of this structure [22]. ESD has few surgical
5 116 complications in comparison with the ablative surgery mentioned above. However, results
6 117 from this type of surgery are inconclusive [23].

7
8 118 If there is no response to non-ablative treatments, treatment with intratympanic gentamicin is
9 119 recommended, and if the disease remains unmanageable and the patient has non-usable
10 120 hearing, labyrinthectomy is advised. Patients should also be referred for vestibular
11 121 rehabilitation therapy in case of chronic balance problems, and clinicians should counsel
12 122 patients with hearing problems about hearing aids.

13 123 *Endolymphatic sac surgery*

14 124 Although surgery on the endolymphatic sac is briefly discussed in the guidelines, it may be
15 125 worth further investigation. The advantage of procedures targeting the endolymphatic sac is
16 126 that they are non-destructive and do therefore not affect the cochlear and vestibular function.
17 127 Apart from decompression of the sac, as is discussed in the guideline [23], shunting or
18 128 drainage of the ES has also been proposed. These techniques involve identification of the
19 129 ES, followed by incision of the sac. A shunt is then placed, enabling drainage of the
20 130 endolymph.

21 131 Several studies were directed to investigate surgery on the endolymphatic [24-26]. Bretlau
22 132 and Thomsen compared ESS to a sham operation (either mastoidectomy or placement of
23 133 ventilation tubes); no differences between the groups was observed. Brinson compared
24 134 shunting to decompression performed on 88 and 108 patients, respectively. He concluded
25 135 that both procedures are effective.

26 136 Multiple histological studies refute the rationale of endolymphatic sac surgery. Firstly, Chung
27 137 et al, performed a histopathological study 15 patients who had undergone ESS [27]. If the
28 138 endolymphatic sac does indeed have a function in resorption of the endolymph but does so
29 139 inadequately, ESS and especially ESD would allow expansion of these structures and would
30 140 therefore diminish hydrops. However, diffuse hydrops on temporal bone was seen in the
31 141 cochlea, the saccule, the utricle, and the ampulla after ESD. The authors conclude that ESD
32 142 does not relieve hydrops in patients with Ménière's disease.

33 143 In addition, if the ES was responsible for endolymph resorption, an increase of hydrops can
34 144 be expected after amputation of the ES. However, Linthicum et al. reported a case in which
35 145 removal of the ES did not lead to an increase of hydrops, as seen on temporal bone
36 146 histopathology [28]. In the assessed samples, Reissner's membrane was attached to the
37 147 spiral ligament in a normal way, without any evidence of hydrops in the cochlea. In

1
2
3 148 conclusion, the role of the ES is not merely absorption of the endolymph and therefore,
4 149 providing more space to allow dilatation is not the solution for the observed hydrops.

6
7 150 The success rates of these surgical interventions vary between 30-95% [2, 4, 22, 29-31]. It
8 151 should be noted that the natural course of MD is also favourable, and it cannot be
9 152 determined to what extent the outcome of procedures are due to the surgical intervention.
11 153 Moreover, the placebo effect may play a major role in the relief of complaints, as 70% of MD
12 154 patients in all groups (all surgical interventions as well as the control groups) experienced
13 155 some relief of complaints. This either implicates a beneficial effect of any surgical
14 156 intervention or of any intervention, be it surgical or non-surgical. This was earlier suggested
15 157 by Thomsen [25].

20 158 *A new technique*

21 159 Recently, a new surgical intervention has been studied by Saliba et al. [32]. A paradigm shift
22 160 for the pathophysiological model of MD underlies this new treatment. Until now it is believed
23 161 that the disease is caused by a surplus of endolymph originating in the inner ear, caused by
24 162 a disequilibrium in the production of endolymph in the inner ear and its resorption in the
25 163 endolymphatic sac [7, 33, 34]. However, Saliba et al. state that the organic substrate of the
26 164 disease - the surplus of endolymph causing the hydrops – also originates in the
27 165 endolymphatic sac.

28 166 The idea that the surplus of endolymph originates in the ES, is supported by two studies that
29 167 suggest that the ES has secretory functions as well, rather than merely a function in
30 168 absorption. In a study of the subcellular structure of the endolymphatic sac in guinea pigs by
31 169 Takumida et al., the presence of dark cells in the endolymphatic sac was shown [35]. These
32 170 cells have a secretory role. Moreover, a study performed by Friis on Lewis rats showed
33 171 hyperactivity of the cells of the endolymphatic sac, leading to an increase of endolymph
34 172 secretion [36]. In conclusion, histological evidence that the ES is –at least in part-
35 173 responsible for the endolymph surplus.

36 174 Based on these findings, Saliba's hypothesis is that in Ménière's disease, there is imbalance
37 175 in the fluid homeostasis of the endolymph at the level of the endolymphatic sac, where the
38 176 increased secretion outweighs the decreased absorption in the ES. Thus, by blocking the
39 177 endolymphatic duct, Saliba aims to decrease the volume of endolymph in the inner ear,
40 178 thereby alleviating the symptoms of Ménière's disease. This operation, referred to as the
41 179 Endolymphatic Duct Blockage (EDB), involves placing a clip on the endolymphatic duct to
42 180 separate the endolymphatic sac from the rest of the inner ear. Benefits of this technique are
43 181 its permanent nature and the fact that it does not destroy the labyrinth or inner ear function.

1
2
3 182 Saliba has performed a randomized trial to study the effect of EDB [32]. The trial compared
4 183 EDB to ESD and was conducted prospectively and non-blinded. There was no comparison to
5
6 184 a group of patients receiving placebo treatment, for instance a sham operation. The results
7
8 185 have been published in 2015 [32] and show that 34 of 35 treated patients were free of vertigo
9
10 186 attacks after EDB surgery. It is interesting to note that the efficacy for the absence of vertigo
11
12 187 attacks following ESD was only reported to be about 40% in Saliba's trial [32]. In earlier
13
14 188 studies by Bretlau and later Thomsen, percentages for both ESD and sham operations were
15
16 189 reported to be as high as 70%. Possibly, this can be explained by the open character of the
17
18 190 Saliba study, causing patients to experience the 'nocebo-effect', caused by feeling like they
19
20 191 have not been treated because they did not have the EDB surgery (but the ESD instead).
21
22 192 The fact that Saliba et al. did not assess outcomes in a double-blinded way is a flaw in
23
24 193 methodology given the high placebo effect of interventions in Ménière disease. Moreover,
25
26 194 randomisation was not stratified and there is a risk of recall bias, as it is not described how
27
28 195 vertigo bouts are recorded. Lastly, all participants were asked to follow the CATS (caffeine,
29
30 196 alcohol, theophylline and salt restricted diet. The role of this diet is not clear.

31
32 197 In a more recent publication by the group of Saliba it is reported that 43 (79%) of a group of
33
34 198 54 patients treated with EDB had an improved quality of life (QoL) [37]. The results of these
35
36 199 studies indicate that EDB may have a favourable effect on both the bouts of vertigo that MD
37
38 200 patients suffer, as on the quality of life. It should be noted that this study was at risk for recall
39
40 201 bias, as patients had to fill out questionnaire in retrospect.

41 202 *EDB pilot*

42 203 In the Netherlands, a pilot group of 34 patients underwent EDB. In this group of 34 patients,
43
44 204 a significant ($p=.001$) improvement of quality of life seen (unpublished data). Three of these
45
46 205 34 patients suffered drop attacks post-operatively, but these symptoms were all resolved
47
48 206 within 8 weeks. In three patients, a postsurgical cerebrospinal fluid (CSF) leakage occurred;
49
50 207 successful surgical reintervention was performed the next day. In addition, EDB surgery was
51
52 208 performed on another group of 60 patients. No adverse events occurred in this group of
53
54 209 patients and most of the patients remained free of vertigo attacks (unpublished data).

55 210 According to the results discussed above, EDB is a promising surgical technique for treating
56
57 211 MD that preserves hearing and equilibrium functions. The current trial further investigates the
58
59 212 effectiveness of the EDB in treating MD, as compared to endolymphatic sac decompression.

60 213

1
2
3 214 **Methods and analysis**

4 215 *Participants*

5 216 Patients will be recruited in the participating centers in the Netherlands. Thirteen hospitals
6
7 217 take part in this study, five of which are academic centers. In order to include only active
8
9 218 Meniere's disease, to avoid interference with follow up and to minimize risk for the patients,
10
11 219 eligibility criteria apply. These can be found in **Table I**. All participants will be informed about
12
13 220 this trial by their own ENT-surgeon. Informed consent can be signed after a two week
14
15 221 reflection period. Each surgeon collects the number of patients that was screened for this
16
17 222 study in order to assess generalizability of the results. This will be done in the patient records
18
19 223 of each hospital. After enrollment, all data will be collected in Castor EDC. All data will be
20
21 224 treated confidentially.

22
23 **Inclusion criteria**

24 Definite unilateral MD according to diagnostic criteria of the Bárány Society (Lopez-
25 Escamez, 2016)

26 More than 3 patient reported attacks in the 6 months prior to inclusion and at least 1
27 attack in the 2 months prior to inclusion

28
29 Non responding to a sufficient extent to conservative medical treatment including at
30 least two sessions of at least one intra-tympanic injection (IT) each with corticosteroids
31 (dexamethasone, methylprednisolone, triamcinolonacetone)

32
33 Dutch health care insurance

34
35 Age \geq 18 years at the start of the trial

36
37
38 **Exclusion criteria**

39 Severe disability (e.g. neurological, orthopedic, cardiovascular) according to the
40 investigator, pregnancy or serious concurrent illness that might interfere with surgery
41 or follow-up.

42
43 Active additional neuro-otologic disorders that may mimic MD (e.g. vestibular migraine
44 (VM), recurrent vestibulopathy, phobic postural vertigo, vertebro-basilar TIAs, acoustic
45 neuroma, congenital disorders, enlarged vestibular aqueduct (EVA)-like or genetic
46 disorders (like DFNA9), cervicogenic dizziness), based on the complete clinical record.

47
48 Unable to undergo MRI (such as gadolinium allergy, claustrophobia, implanted non-
49 MRI compatible device of material, BMI)

50
51 Previous ear surgery for MD (IT injection is not an exclusion criterion)

52
53 Deafness of the contralateral ear

54
55 Language difficulties

56
57 Active otitis media (with or without effusion)

58
59
60

Unable or unwilling to use app-based diary

225 *Table 1. Inclusion and exclusion criteria*

226

227 *Interventions*

228 All participants will undergo surgery. Participants will be allocated in the EDB group or
229 endolymphatic sac decompression group using an automated telephone randomised service
230 (Castor). Participants will be stratified according to gender and duration of MD (recent-onset
231 versus mature MD participants). A “recent-onset MD participant” is defined as having their
232 first MD vertigo attack in the two years prior to inclusion. “Mature MD participants” have had
233 their first MD vertigo attack more than two years prior to inclusion. By stratification for the
234 duration of the disease, the effect of the natural course of disease on the outcome is
235 reduced.

236 The surgeries will be performed by two surgeons. One surgeon is experienced in this
237 intervention and will act as proctor in all surgeries carried out for this trial. The second
238 surgeon is the ENT-surgeon who included the patients in this study. By working with only one
239 proctor who attends all surgeries, we aim to minimize outcome heterogeneity due to surgeon
240 specific factors.

241 The two ear surgeons will be present up to wherein the sac is completely skeletonized. Then
242 one of the surgeons will leave the OR. The randomization for clip or decompression
243 operation will be performed using the automated telephone randomized service. The surgeon
244 who leaves the OR will take care of the follow up of the patient and does not know whether
245 the clip has been placed or not.

246 *EDB surgery protocol*

247 Surgery is performed as described by Saliba [32]. First, a canal wall-up mastoidectomy is
248 performed: the mastoid tegmen, sigmoid sinus, and sinodural angle are identified, and the
249 posterior bony external ear canal wall is thinned. The posterior semi-circular canal (PSCC)
250 and the dura mater of the posterior fossa are identified. Using the prominence of the
251 horizontal semi-circular canal, Donaldson’s line is identified to approximate the position of the
252 endolymphatic sac. The bone over the sac and the dura are thinned with diamond burrs. The
253 sac is completely skeletonized. The infralabyrinthine dura is exposed because the main body
254 of the sac and its lumen often lie within this area. The bone of the vestibular aqueduct
255 operculum is dissected. The posterior fossa dura from the retrolabyrinthine bone medial to
256 the sac around the endolymphatic duct is exposed in order to identify the duct in its superior
257 and inferior part in continuity from the endolymphatic sac, and to create a place to insert the

258 tips of the instrument to clip the duct. At this level, care must be taken not to traumatize the
259 dura, which is often thin.

260 Finally, the dissected endolymphatic duct is blocked with an adequate titanium clip (Weck
261 Horizon, size 'micro' to 'wide, Teleflex). The size and numbers of clips used will be
262 determined intraoperatively. The titanium clips are applied by using a clip applier (Weck
263 Horizon). In the case of tearing of the dura leading to liquor leakage, this will be treated with
264 tisseel, fascie and novacol. Bone paste is collected during surgery and the cortex is restored
265 with a mix of bone paste, ofloxacin (3 mg/ml, Bausch&Lomb) and Tisseel (4 ml, Baxter
266 B.V.).

267 *Decompression surgery protocol*

268 The same surgical procedure is carried out in the decompression group. However, after
269 identification of the posterior canal, and the ES will be decompressed. No clips will be
270 placed. The cortex is restored in the same procedure as described above.

271 *Use of escape medication*

272 Use of any co-intervention, such as intratympanic injection of steroid or use of anti-emetics,
273 are allowed and will be based on the participants' experience of vertigo attack frequency and
274 patient-doctor preference (shared decision-making). Shared decision-making ensures wide
275 applicability of study results and reflects daily medical practice.

276 *Follow up and outcome measures*

277 From the moment of inclusion, all participants will use an app-based diary (the DizzyQuest
278 App [38] in which they fill out a daily questionnaire. Attacks are also reported in this app. All
279 participants receive an individual tailored vestibular rehabilitation program after surgery.
280 Follow up visits will take place at 1 week, 3 months, 6 months and 12 months after surgery.
281 What outcomes will be measured at what moment can be found in **Table II**. All data will be
282 stored in Castor EDC.

Moment in trial	Type of follow up	Outcomes
From moment of inclusion until 1 year after surgery		Daily questionnaire in app
>4 weeks before surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	Questionnaires	Baseline characteristics HADS DHI

		THI FLS EQ 5D VAS SF36 NPQ Assessment of expectations patient VADL VAP
	Imaging	MRI CT
	Other	PTA Calorigram
1 week after surgery	ENT-surgeon	Standard postoperative care (video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
3 months after surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	Questionnaires	DHI THI FLS EQ 5D VAS SF36 iMCQ iPCQ
	Imaging	MRI
	Other	PTA
6 months after surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)

	Questionnaires	DHI THI FLS E Q 5D VAS SF36 iMCQ iPCQ
	Imaging	-
	Other	PTA
12 months after surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	Questionnaires	DHI THI FLS EQ 5D VAS SF36 iMCQ iPCQ VADL VAP
	Imaging	MRI
	Other	PTA Calorigram

283

284 We hypothesize that the number of patients without vertigo spells at 12 months follow up will
 285 be higher in the group that has undergone EDB than in the decompression group. Secondary
 286 outcomes include minimally clinically significant differences in cumulative incidence of vertigo
 287 bouts, hearing, use of escape medication, co-interventions, complications of surgery,
 288 questionnaire outcomes, cost effectiveness analysis, budget impact analysis, endolymphatic
 289 hydrops on MRI and multiple physiotherapeutical outcomes. We hypothesize that the
 290 outcomes of these measures will be better in participants undergoing EDB compared to
 291 participants who have had a decompression operation.

1
2
3 292 The sample size for this RCT was computed using software package PASS 11. The sample
4 293 size calculation is based on the study performed by Saliba [32], in which complete control of
5 294 vertigo was reached in 96,5% of the patients who underwent EDB. According to literature,
6 295 endolymphatic sac decompression is effective is $\pm 70\%$ of the patients [26, 30, 31].
9

10 296 We compare MD participants undergoing an operation with clip (EDB group: A group)
11 297 independently with MD participants undergoing operation without clip (decompression group:
12 298 B group). Null hypothesis is that the percentage points difference between groups
13 299 percentages is nil ($p_A=p_B$), with two-sided alternative hypothesis ($p_A \neq p_B$) and with
14 300 anticipated 25% percent difference ($p_A= 95\%$ and $p_B = 70\%$). Power is at least 80%. The
15 301 chance of a false positive finding for either of the analyses is controlled at the 5% level
16 302 (family wise error rate). To obtain a power of at least 80-% for Fisher's Exact test, the
17 303 required sample size is 32 in groups A and B (allocation ratio =1). Loss to follow-up will likely
18 304 occur in a small percentage of cases. No selective loss to follow-up is anticipated and a
19 305 missing-at-random assumption is reasonable. Missing outcomes will therefore be imputed
20 306 using multiple imputation in the main analysis. Two sensitivity analyses will be conducted as
21 307 well, where missing outcomes will be treated as failures or success, respectively. In this case
22 308 the sample size would be 42 in group A and B (allocation ratio = 1). The total number of
23 309 participants will be 84.

310 *Endolymphatic hydrops on MRI*

311 We hypothesize that EDB results in a decrease in hydrops and perilymph signal intensity.
312 These two parameters will be measured pre-operatively, as well as 3-months and 12-months
313 post-operatively to assess if the hydrops diminishes after EDB and is clinically relevant.

314 *Data analysis*

315 All collected data will be accessible for the coordinating investigator, the principal investigator
316 and for the investigators involved in carrying out analyses.

317 The primary outcome is defined as being attack free at 12 months follow-up. All statistical
318 tests will be performed two-sided at a significance (α) level of 5%. When using confidence
319 limits, the confidence interval will be 95%. The primary analysis will be performed following
320 the intention-to-treat principle. A chi-square test (or Fisher's exact test) will be performed on
321 the primary outcome variable data (number of patients free of vertigo attacks at 12 months
322 post-operatively, in EDB vs endolymphatic sac decompression group). Although
323 randomization is stratified, the impact of gender and duration of MD is deemed small. These
324 variables will only be added as covariates to the analysis if they are independently
325 associated with the outcome. In the case, a logistic regression will be performed.

1
2
3 326 The daily questionnaire taken via the DizzyQuest app is likely to contain missing data. All
4 327 other missing data will be labelled 'NAmissing' in SPSS. Multiple imputation will be used to
5 328 create complete data sets. Depending on the missing data pattern, different strategies will be
6 329 followed. Preferably, 'wide' data format will be used to account for time dependent effects. As
7 330 an alternative for larger percentages of missingness, data will be imputed in long format,
8 331 ignoring time dependent effects.

9
10
11
12
13 332 The outcome will be determined from the imputed App-data. It is expected that attacks are
14 333 reported reliably and missing data can be reliably imputed as being attack free. In principle, a
15 334 patient can be sometimes imputed as having an attack on otherwise as being attack-free. To
16 335 account for these potential cases, a cut-off of 10% for the attack probability (as the imputed
17 336 frequency for having an attack) will be used to determine presence/absence of attacks.

18
19
20
21
22 337 The Patient Reported Outcome Measures (PROMs) used in this study are assumed to be
23 338 continuous numerical and will be tested checked for near-Gaussian distribution normality
24 339 before analysis. Results will be described as means (with 95%CI) in case of near-Gaussian
25 340 distribution or, otherwise medians (with IQR) will be presented at each time point.
26 341 Categorical outcomes will be presented in numbers of participants with accompanying
27 342 percentages of group total.

28
29
30
31
32 343 All secondary outcomes will be analyzed using a linear mixed model (EDB versus
33 344 decompression group) at the different time measurement point.

345 *Economic evaluation*

346 A one-year trial-based cost-effectiveness analysis (costs per prevented vertigo-attack, from a
347 healthcare perspective), a cost-utility analysis (costs per QALY, from a societal perspective),
348 and a budget-impact analysis will be performed. Societal costs will be assessed from the
349 patients' medical records and from patient questionnaires at 3,6 and 12 months. QALYs will
350 be calculated as the area under the utility curve, estimated using the Dutch tariff for the EQ-
351 5D-5L at 0, 3, 6, 12 months (and the EuroQol visual analogue scale with power
352 transformation as secondary analysis). Average costs and patient outcome will be compared
353 according to intention to treat, using net benefit analysis, and multiple imputation to account
354 for missing data.

355 *Patient and public involvement*

356 Several patients and the patient support group for hearing and equilibrium disorders were
357 involved in the design of this trial. Patients have provided feedback on feasibility of the
358 number of questionnaires. The patient support group will also be involved in recruitment of
359 patients, by spreading information about the trial. During the conduct of the trial, the
60

1
2
3 360 frequency of questionnaires (mainly the app based diary) will be evaluated with the
4 361 participants.

5
6
7 362 The SPIRIT reporting guidelines were used for publication of this protocol [39].
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 363 **Ethics and dissemination**

4 364 *Ethics.*

5
6 365 The protocol was reviewed and approved by the Medical Research Ethics Committee Leiden
7
8 366 The Hague Delft. The study will be conducted according to the principles of the Declaration
9
10 367 of Helsinki (October 2013) and in accordance with the Medical Research Involving Human
11
12 368 Subjects Act (WMO, 26 February 1998) and the International Conference on Harmonization
13
14 369 Good Clinical Practice (ICH GCP, November 2016).

15 370 This trial is registered in the Netherlands Trial Register (<https://www.trialregister.nl/trial/9095>)
16
17 371 and in the ISRCTN registry (<https://www.isrctn.com/ISRCTN12074571>).

18
19 372 *Patient safety.*

20 373 A Data Safety Monitoring Board (DSMB) was established to monitor the safety of the
21
22 374 participants throughout the trial. The three members are not in any other way involved in the
23
24 375 trial and have therefore no conflict of interest with the sponsor of the study. An interim
25
26 376 analysis of the data for the first 21 participants 3 months after surgery will be performed,
27
28 377 focusing on safety of the surgical procedures. The DSMB will assess the results and discuss
29
30 378 the outcome, and give advice whether or not to continue the study. Termination of the trial
31
32 379 will be considered if there are more (serious) adverse events than expected, that are related
33
34 380 to the intervention. Moreover, monitoring of the conduct of the study will be performed,
35
36 381 according to the monitor plan that was written.

37 382 All serious adverse events will be reported in the official tool of the Dutch Central Committee
38
39 383 on Research Involving Human Subjects.

40 384 An emergency phone number will be provided to the participants, for when debinding is
41
42 385 necessary because of a medical emergency.

43 386 *After follow up.*

44 387 When the last patient has been followed up for a year, patients can choose to be debinded if
45
46 388 they wish. If the patient was allocated to the EDB group but still suffers vertigo bouts, a CT-
47
48 389 scan will be performed to assess if the clip is correctly in place. If the results of this trial are in
49
50 390 favour of EDB, patients in the decompression group who still suffer vertigo attacks will be
51
52 391 offered EDB. In case of a favourable outcome of EDB, a trajectory for implementation in the
53
54 392 current Dutch health care system is also foreseen.

55 393 *Publication of results.*

56 394 Results of this study will be published in international peer-reviewed scientific journals and
57
58 395 will be presented on (inter)national scientific conferences and meetings. Individual centers
59
60 396 included in this multicenter trial will not report or publish data from this center alone. Transfer
397 of ownership of the data will be reported to the appropriate authority/authorities, as required

1
2
3 398 by the applicable regulatory requirement(s). All publications and presentations are to protect
4 399 the research integrity of the participants and objectives of the study. No data will be
5 400 presented or released that may break the masking of the study trial. The timing of
6 401 presentation and/or publications of the primary and/or secondary outcomes will be secured
7 402 by the supervising researchers and will be communicated first with all centers involved.
8
9
10
11 403 All data remains stored in Castor for 15 years after termination of the trial.
12
13

14 404
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

405 **List of abbreviations**

BMI	Body mass index
CI	Confidence interval
CSF	Cerebrospinal fluid
CT	Computed tomography
DGI	Dynamic gait index
DHI	Dizziness handicap index
DSMB	Data Safety Monitoring Board
EDB	Endolymphatic duct blockage
ENT	Ear, nose, throat
EQ 5D	EuroQol 5D
ES	Endolymphatic sac
ESD	Endolymphatic sac decompression
ESS	Endolymphatic sac surgery
EVA	Enlarged vestibular aqueduct
FLS	Functional level scale
HIT	Head impulse test
IQR	Interquartile range
iMCQ	IMTA Medical Cost Questionnaire
iPCQ	IMTA Productivity Cost Questionnaire
IT	Intratympanic
MD	Meniere's disease
MRI	Magnetic resonance imaging
NPQ	Niigata PPPD Questionnaire
OR	Operating room
PROM	Patient reported outcome measure
PSCC	Posterior semi-circular canal
PTA	Pure-tone average
QALY	Quality adjusted life year
QoL	Quality of life
RCT	Randomized controlled trial
SF36	Short Form Health Survey 36
THI	Tinnitus handicap index

1		
2		
3	TIA	Transient ischemic attack
4		
5	VADL	Vestibular Disorders Activities of Daily Living Scale
6		
7	VAP	Vestibular activities and participation questionnaire
8		
9	VAS	Visual analogue score
10		
11	VM	Vestibular migraine

406

407

408 **Authors' contributions:** state how each author was involved in writing the protocol.

409 A.A. Schenck 1, 2

410 J.M. Kruyt 3

411 P.P. van Benthem 2

412 S.C. Cannegieter 4

413 W.B. Van den Hout 5

414 S. Boehringer 6

415 S. Hammer 7

416 S.P.M. Hombergen 8

417 H.M. Blom 1, 2, 9

418 All authors were involved in the conception of the trial, writing of the protocol and critical
419 revision for intellectual content. All authors read and approved of the final version.

420

421

422 1 Department of Otorhinolaryngology, HagaHospital, the Hague, the Netherlands

423 2 Department of Otorhinolaryngology, Leiden University Medicae Centre, Leiden, the
424 Netherlands

425 3 Department of Otorhinolaryngology, Haaglanden Medical Center, the Hague, the
426 Netherlands

427 4 Department of Clinical Epidemiology, Leiden University Medicae Centre, Leiden, the
428 Netherlands

1
2
3 429 5 Medical Decision Making & Quality of Care, Leiden University Medica Centre, Leiden, the
4 430 Netherlands

5
6
7 431 6 Department of Statistics, Leiden University Medica Centre, Leiden, the Netherlands

8
9 432 7 Department of Radiology, HagaHospital, the Hague, the Netherlands

10
11 433 8 Department of Physiotherapy, HagaHospital, the Hague, the Netherlands

12
13 434 9 Department of Otorhinolaryngology, Antwerp University Hospital, Belgium

14
15 435

16 17 436 **Roles and responsibilities**

18
19 437 The authors of this protocol form the trial steering committee. All were engaged in study
20 438 design and will be involved in analysis, interpretation of data, writing of the report and the
21 439 decision to submit the outcomes for publication. AS is the coordinating investigator and HB is
22 440 the principal investigator and are responsible for data collection and management.

23
24
25 441

26 27 442 **Funding statement**

28
29 443 This work was supported by the 'Potentially Promising Care' subsidy from the Dutch National
30 444 Health Care Institute and ZonMw (project number 80-86200-98-19017).

31
32
33 445

34 35 446 **Competing interests statement**

36
37 447 None to declare.

38
39
40 448

41 42 449 **Acknowledgements**

43
44 450 The authors thank dr. Y. Smulders for her suggestion to publish the protocol.

45
46
47 451

48 49 452 **Full references**

- 50
51
52
53 453 1. Lopez-Escamez, J.A., et al., *Diagnostic criteria for Menière's disease*. J Vestib Res,
54 454 2015. **25**(1): p. 1-7.
55 455 2. Pullens, B., H.P. Verschuur, and P.P. van Benthem, *Surgery for Ménière's disease*.
56 456 Cochrane Database Syst Rev, 2013. **2013**(2): p. Cd005395.
57 457 3. Portmann, G., *The old and new in Meniere's disease -- over 60 years in retrospect*
58 458 *and a look to the future*. Otolaryngol Clin North Am, 1980. **13**(4): p. 567-75.

- 1
- 2
- 3 459 4. Silverstein, H., E. Smouha, and R. Jones, *Natural history vs. surgery for Ménière's*
- 4 460 *disease*. *Otolaryngol Head Neck Surg*, 1989. **100**(1): p. 6-16.
- 5 461 5. Perez-Garrigues, H., et al., *Time course of episodes of definitive vertigo in Meniere's*
- 6 462 *disease*. *Arch Otolaryngol Head Neck Surg*, 2008. **134**(11): p. 1149-54.
- 7 463 6. Van Esch, B.F., et al., *Age of onset of Ménière's disease in the Netherlands: data*
- 8 464 *from a specialised dizziness clinic*. *J Laryngol Otol*, 2016. **130**(7): p. 624-7.
- 9 465 7. Merchant, S.N., J.C. Adams, and J.B. Nadol, Jr., *Pathophysiology of Meniere's*
- 10 466 *syndrome: are symptoms caused by endolymphatic hydrops?* *Otol Neurotol*, 2005.
- 11 467 **26**(1): p. 74-81.
- 12 468 8. Nakashima, T., et al., *Visualization of endolymphatic hydrops in patients with*
- 13 469 *Meniere's disease*. *Laryngoscope*, 2007. **117**(3): p. 415-20.
- 14 470 9. Naganawa, S. and T. Nakashima, *Visualization of endolymphatic hydrops with MR*
- 15 471 *imaging in patients with Ménière's disease and related pathologies: current status of*
- 16 472 *its methods and clinical significance*. *Jpn J Radiol*, 2014. **32**(4): p. 191-204.
- 17 473 10. Baráth, K., et al., *Detection and grading of endolymphatic hydrops in Ménière disease*
- 18 474 *using MR imaging*. *AJNR Am J Neuroradiol*, 2014. **35**(7): p. 1387-92.
- 19 475 11. van Steekelenburg, J.M., et al., *Value of Endolymphatic Hydrops and Perilymph*
- 20 476 *Signal Intensity in Suspected Ménière Disease*. *AJNR Am J Neuroradiol*, 2020. **41**(3):
- 21 477 p. 529-534.
- 22 478 12. Attyé, A., et al., *In vivo imaging of saccular hydrops in humans reflects sensorineural*
- 23 479 *hearing loss rather than Meniere's disease symptoms*. *Eur Radiol*, 2018. **28**(7): p.
- 24 480 2916-2922.
- 25 481 13. Shi, S., P. Guo, and W. Wang, *Magnetic Resonance Imaging of Ménière's Disease*
- 26 482 *After Intravenous Administration of Gadolinium*. *Ann Otol Rhinol Laryngol*, 2018.
- 27 483 **127**(11): p. 777-782.
- 28 484 14. Shojaku, H., et al., *Epidemiologic characteristics of definite Ménière's disease in*
- 29 485 *Japan. A long-term survey of Toyama and Niigata prefectures*. *ORL J*
- 30 486 *Otorhinolaryngol Relat Spec*, 2005. **67**(5): p. 305-9.
- 31 487 15. Stahle, J., C. Stahle, and I.K. Arenberg, *Incidence of Ménière's disease*. *Arch*
- 32 488 *Otolaryngol*, 1978. **104**(2): p. 99-102.
- 33 489 16. Wladislavosky-Waserman, P., et al., *Meniere's disease: a 30-year epidemiologic and*
- 34 490 *clinical study in Rochester, Mn, 1951-1980*. *Laryngoscope*, 1984. **94**(8): p. 1098-102.
- 35 491 17. Kotimäki, J., et al., *Prevalence of Meniere disease in Finland*. *Laryngoscope*, 1999.
- 36 492 **109**(5): p. 748-53.
- 37 493 18. Adrion, C., et al., *Efficacy and safety of betahistine treatment in patients with*
- 38 494 *Meniere's disease: primary results of a long term, multicentre, double blind,*
- 39 495 *randomised, placebo controlled, dose defining trial (BEMED trial)*. *Bmj*, 2016. **352**: p.
- 40 496 h6816.
- 41 497 19. McRackan, T.R., et al., *Intratympanic dexamethasone as a symptomatic treatment for*
- 42 498 *Ménière's disease*. *Otol Neurotol*, 2014. **35**(9): p. 1638-40.
- 43 499 20. Patel, M., et al., *Intratympanic methylprednisolone versus gentamicin in patients with*
- 44 500 *unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness*
- 45 501 *trial*. *Lancet*, 2016. **388**(10061): p. 2753-2762.
- 46 502 21. Harner, S.G., et al., *Long-term follow-up of transtympanic gentamicin for Ménière's*
- 47 503 *syndrome*. *Otol Neurotol*, 2001. **22**(2): p. 210-4.
- 48 504 22. Sennaroglu, L., et al., *Intratympanic dexamethasone, intratympanic gentamicin, and*
- 49 505 *endolymphatic sac surgery for intractable vertigo in Meniere's disease*. *Otolaryngol*
- 50 506 *Head Neck Surg*, 2001. **125**(5): p. 537-43.
- 51 507 23. Basura, G.J., et al., *Clinical Practice Guideline: Ménière's Disease*. *Otolaryngol Head*
- 52 508 *Neck Surg*, 2020. **162**(2_suppl): p. S1-s55.
- 53 509 24. Bretlau, P., et al., *Placebo effect in surgery for Ménière's disease: nine-year follow-*
- 54 510 *up*. *Am J Otol*, 1989. **10**(4): p. 259-61.
- 55 511 25. Thomsen, J., et al., *Placebo effect in surgery for Ménière's disease. A double-blind,*
- 56 512 *placebo-controlled study on endolymphatic sac shunt surgery*. *Arch Otolaryngol*,
- 57 513 **1981**. **107**(5): p. 271-7.

- 1
2
3 514 26. Brinson, G.M., D.A. Chen, and M.A. Arriaga, *Endolymphatic mastoid shunt versus*
4 515 *endolymphatic sac decompression for Ménière's disease*. Otolaryngol Head Neck
5 516 Surg, 2007. **136**(3): p. 415-21.
6 517 27. Chung, J.W., et al., *Histopathology after endolymphatic sac surgery for Ménière's*
7 518 *syndrome*. Otol Neurotol, 2011. **32**(4): p. 660-4.
8 519 28. Linthicum, F.H. and F. Santos, *Endolymphatic sac amputation without hydrops*. Otol
9 520 Neurotol, 2011. **32**(2): p. e12-3.
10 521 29. Huang, T.S., C.C. Lin, and Y.L. Chang, *Endolymphatic sac surgery for Meniere's*
11 522 *disease. A cumulative study of twelve years' experience*. Acta Otolaryngol Suppl,
12 523 1991. **485**: p. 145-54.
13 524 30. Durland, W.F., Jr., G.M. Pyle, and N.P. Connor, *Endolymphatic sac decompression*
14 525 *as a treatment for Meniere's disease*. Laryngoscope, 2005. **115**(8): p. 1454-7.
15 526 31. Convert, C., et al., *Outcome-based assessment of endolymphatic sac decompression*
16 527 *for Ménière's disease using the Ménière's disease outcome questionnaire: a review of*
17 528 *90 patients*. Otol Neurotol, 2006. **27**(5): p. 687-96.
18 529 32. Saliba, I., et al., *Endolymphatic duct blockage: a randomized controlled trial of a novel*
19 530 *surgical technique for Ménière's disease treatment*. Otolaryngol Head Neck Surg,
20 531 2015. **152**(1): p. 122-9.
21 532 33. Semaan, M.T. and C.A. Megerian, *Contemporary perspectives on the*
22 533 *pathophysiology of Meniere's disease: implications for treatment*. Curr Opin
23 534 Otolaryngol Head Neck Surg, 2010. **18**(5): p. 392-8.
24 535 34. Salt, A.N. and S.K. Plontke, *Endolymphatic hydrops: pathophysiology and*
25 536 *experimental models*. Otolaryngol Clin North Am, 2010. **43**(5): p. 971-83.
26 537 35. Takumida, M., et al., *Three-dimensional ultrastructure of the endolymphatic sac*. Arch
27 538 Otorhinolaryngol, 1987. **244**(2): p. 117-22.
28 539 36. Friis, M., et al., *Experimental hyperactivity of the endolymphatic sac*. Audiol
29 540 Neurotol, 2013. **18**(2): p. 125-33.
30 541 37. Gabra, N., et al., *Endolymphatic duct blockage: quality of life assessment of a novel*
31 542 *surgical technique for Ménière disease*. Eur Arch Otorhinolaryngol, 2016. **273**(10): p.
32 543 2965-73.
33 544 38. Martin, E.C., et al., *Introducing the DizzyQuest: an app-based diary for vestibular*
34 545 *disorders*. J Neurol, 2020. **267**(Suppl 1): p. 3-14.
35 546 39. Chan, A.W., et al., *SPIRIT 2013 explanation and elaboration: guidance for protocols*
36 547 *of clinical trials*. BMJ, 2013. **346**: p. e7586.
37
38
39 548
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Page
	Reporting Item	Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	12
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	NA
7				
8	data set		Registration Data Set	
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	15
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	14
21				
22	responsibilities:			
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	15
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	15
39			design; collection, management, analysis, and	
40	responsibilities:		interpretation of data; writing of the report; and the	
41			decision to submit the report for publication, including	
42	sponsor and funder		whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	15
53			coordinating centre, steering committee, endpoint	
54	responsibilities:		adjudication committee, data management team, and	
55				
56	committees			
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-6
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	6
Objectives	#7	Specific objectives or hypotheses	6
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	6
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	7
2			applicable, eligibility criteria for study centres and	
3			individuals who will perform the interventions (eg,	
4			surgeons, psychotherapists)	
5				
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	7-8
12			replication, including how and when they will be	
13	description		administered	
14				
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	13
20			interventions for a given trial participant (eg, drug dose	
21	modifications		change in response to harms, participant request, or	
22			improving / worsening disease)	
23				
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	NA
30			and any procedures for monitoring adherence (eg, drug	
31	adherence		tablet return; laboratory tests)	
32				
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	8
37			permitted or prohibited during the trial	
38	concomitant care			
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	8-10
43			specific measurement variable (eg, systolic blood	
44			pressure), analysis metric (eg, change from baseline, final	
45			value, time to event), method of aggregation (eg, median,	
46			proportion), and time point for each outcome. Explanation	
47			of the clinical relevance of chosen efficacy and harm	
48			outcomes is strongly recommended	
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1 2 3 4 5 6 7 8 9	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Table 2
10 11 12 13 14 15 16 17 18 19 20	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9
21 22 23 24 25	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	7
26 27 28 29 30 31 32 33 34 35	Methods: Assignment of interventions (for controlled trials)			
36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7
53 54 55 56 57 58 59 60	Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque,	7

1		sealed envelopes), describing any steps to conceal the	
2			
3		sequence until interventions are assigned	
4			
5			
6	Allocation:	#16c Who will generate the allocation sequence, who will enrol	7
7			
8	implementation	participants, and who will assign participants to	
9			
10		interventions	
11			
12			
13	Blinding (masking)	#17a Who will be blinded after assignment to interventions (eg,	7
14			
15		trial participants, care providers, outcome assessors, data	
16			
17		analysts), and how	
18			
19			
20			
21	Blinding (masking):	#17b If blinded, circumstances under which unblinding is	12
22			
23	emergency	permissible, and procedure for revealing a participant's	
24			
25	unblinding	allocated intervention during the trial	
26			
27			
28			
29	Methods: Data		
30			
31	collection,		
32			
33	management, and		
34			
35	analysis		
36			
37			
38			
39	Data collection plan	#18a Plans for assessment and collection of outcome,	8
40			
41		baseline, and other trial data, including any related	
42			
43		processes to promote data quality (eg, duplicate	
44			
45		measurements, training of assessors) and a description	
46			
47		of study instruments (eg, questionnaires, laboratory tests)	
48			
49		along with their reliability and validity, if known. Reference	
50			
51		to where data collection forms can be found, if not in the	
52			
53		protocol	
54			
55			
56			
57			
58			
59			
60			

1	Data collection plan:	#18b	Plans to promote participant retention and complete	8
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	8
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	9
19			outcomes. Reference to where other details of the	
20			statistical analysis plan can be found, if not in the protocol	
21				
22				
23	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	9
24			adjusted analyses)	
25	analyses			
26				
27				
28	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	9-10
29			adherence (eg, as randomised analysis), and any	
30	population and		statistical methods to handle missing data (eg, multiple	
31	missing data		imputation)	
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46	Methods: Monitoring			
47				
48				
49	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	12
50			summary of its role and reporting structure; statement of	
51	formal committee		whether it is independent from the sponsor and	
52			competing interests; and reference to where further	
53				
54				
55				
56				
57				
58				
59				
60				

1 details about its charter can be found, if not in the
 2 protocol. Alternatively, an explanation of why a DMC is
 3 not needed
 4
 5
 6
 7

8	Data monitoring:	#21b	Description of any interim analyses and stopping	12
9	interim analysis		guidelines, including who will have access to these	
10			interim results and make the final decision to terminate	
11			the trial	
12				
13				
14				
15				
16				
17				
18	Harms	#22	Plans for collecting, assessing, reporting, and managing	12
19			solicited and spontaneously reported adverse events and	
20			other unintended effects of trial interventions or trial	
21			conduct	
22				
23				
24				
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if	12
29			any, and whether the process will be independent from	
30			investigators and the sponsor	
31				
32				
33				
34				
35	Ethics and			
36	dissemination			
37				
38				
39				
40				
41	Research ethics	#24	Plans for seeking research ethics committee / institutional	12
42	approval		review board (REC / IRB) approval	
43				
44				
45				
46	Protocol	#25	Plans for communicating important protocol modifications	n/a
47	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
48			relevant parties (eg, investigators, REC / IRBs, trial	
49			participants, trial registries, journals, regulators)	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential	7
2			trial participants or authorised surrogates, and how (see	
3			Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
10	ancillary studies		participant data and biological specimens in ancillary	
11			studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	7
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	15
27	interests		investigators for the overall trial and each study site	
28				
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	9
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	12
40	trial care		compensation to those who suffer harm from trial	
41			participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	12
48	trial results		results to participants, healthcare professionals, the	
49			public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1 2 3 4 5 6 7 8 9 10 11 12 13	Dissemination policy: #31b authorship	Authorship eligibility guidelines and any intended use of professional writers	12
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32	Dissemination policy: #31c reproducible research	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Informed consent materials	#32 Model consent form and other related documentation given to participants and authorised surrogates	n/a
	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 14. June 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Study protocol for a double blinded, randomised controlled trial to assess the effectiveness of endolymphatic duct blockage versus endolymphatic sac decompression in patients with intractable Ménière's disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054514.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Jul-2021
Complete List of Authors:	Schenck, Annejet; Haga Hospital, Otorhinolaryngology Kruyt, Josephina; Medical Centre Haaglanden, Otorhinolaryngology van Benthem, Peter Paul; Leiden University Medical Centre, Departement of Otorhinolaryngology Cannegieter, Suzanne; Leiden University Medical Centre, Leiden, Department of Thrombosis and Hemostasis; Leiden University Medical Centre, Department of Clinical Epidemiology van den Hout, Wilbert; University Medical Center Leiden, Medical Decisionmaking Böhringer, Stefan; Leiden University Medical Center, Biomedical Data Sciences Hammer, Sebastiaan; Haga Hospital, Department of Radiology Hombergen, Susan; Haga Hospital, Department of Physiotherapy Blom, H.M.; Haga Hospital, Department of Otorhinolaryngology
Primary Subject Heading:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology
Keywords:	Adult otolaryngology < OTOLARYNGOLOGY, Audiology < OTOLARYNGOLOGY, Head & neck surgery < OTOLARYNGOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **TITLE PAGE**

4
5 2 **Title**

6
7 3 Study protocol for a double blinded, randomised controlled trial to assess the effectiveness of
8 4 endolymphatic duct blockage versus endolymphatic sac decompression in patients with
9 5 intractable Ménière's disease.

10
11 6 Protocol version 6, June 16th, 2021
12
13
14
15
16

17 8 **Authors**

18 9 A.A. Schenck 1, 2, *

19
20
21 10 J.M. Kruyt 3

22
23 11 P.P. van Benthem 2

24
25 12 S.C. Cannegieter 4

26
27 13 W.B. Van den Hout 5

28
29 14 S. Boehringer 6

30
31 15 S. Hammer 7

32
33 16 S.P.M. Hombergen 8

34
35 17 H.M. Blom 1, 2, 9
36
37
38
39
40

41 19 1 Department of Otorhinolaryngology, HagaHospital, the Hague, the Netherlands

42
43 20 2 Department of Otorhinolaryngology, Leiden University Medical Centre, Leiden, the
44 21 Netherlands

45
46
47 22 3 Department of Otorhinolaryngology, Haaglanden Medical Centre, the Hague, the
48 23 Netherlands

49
50
51 24 4 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, the
52 25 Netherlands

53
54
55 26 5 Medical Decision Making & Quality of Care, Leiden University Medical Centre, Leiden, the
56 27 Netherlands

57
58 28 6 Department of Statistics, Leiden University Medical Centre, Leiden, the Netherlands
59
60

1
2
3 29 7 Department of Radiology, HagaHospital, the Hague, the Netherlands
4
5 30 8 Department of Physiotherapy, HagaHospital, the Hague, the Netherlands
6
7 31 9 Department of Otorhinolaryngology, Antwerp University Hospital, Belgium
8
9

10 32

11 33 * Corresponding author

12
13 34 Address: Els Borst-Eilersplein 275, postbox 40551, 2545 AA, the Hague, the Netherlands

14
15 35 Email: j.schenck@hagaziekenhuis.nl, telephone: 0031 70 210 2602, fax: 0031 70 210 4023

16
17 36

18
19
20 37 **Keywords**

21 38 Meniere's disease

22 39 Endolymphatic duct blockage

23 40 Vertigo

24 41 Endolymphatic hydrops

25
26 42

27
28 43 **Word Count:** 4349 words
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

44 **Abstract**

45 *Introduction.* Outcomes of surgery for Meniere's disease (MD) remain discordant. Recently, a
46 new surgical procedure in which the endolymphatic duct is clipped, was proposed. To date,
47 only one prospective trial assessing this technique was published, yielding promising results.
48 The present protocol describes a prospective, double blinded, randomized controlled trial
49 that will be carried out to assess effectiveness of this surgical intervention.

50
51 *Methods.* Eighty-four patients with intractable Meniere's disease will be recruited from 13
52 hospitals in the Netherlands. Intraoperatively, randomization will determine whether
53 endolymphatic duct blockage (EDB) or endolymphatic sac decompression (ESD) will be
54 performed. Randomization will be 1:1 stratified for gender and duration of MD (recent onset
55 versus mature MD). All participants receive vestibular rehabilitation after surgery. Patients
56 are followed up during one year after surgery. Follow up visits will take place at 1 week, 3
57 months, 6 months and 12 months after surgery. The main study endpoint is proportion of
58 patients who are free of vertigo spells at 12 months post-operatively. Secondary parameters
59 include cumulative number of vertigo bouts, co-intervention, tinnitus, hearing, quality of life,
60 cost-effectiveness and a budget impact analysis. Total duration of the study is 4 years.

61
62 *Analysis.* The primary analysis will follow the intention-to-treat principle. For the primary
63 outcome, a chi-square test will be performed. Secondary outcomes will be analysed using a
64 linear mixed model (EDB vs decompression group) at the different time measurement point.

65
66 *Ethics and dissemination.* This study was reviewed and approved by a board of specialists
67 before funding was obtained, as well as by the Medical Research Ethics Committee Leiden
68 The Hague Delft and the boards of all participating centres. Results of this study will be
69 published in international peer-reviewed scientific journals and will be presented on
70 (inter)national scientific conferences and meetings.

71 **Strengths and limitations of this study**

- 72 - In this study, both patient and clinician will remain blinded throughout the follow up period to
73 minimize bias
- 74 - The prospective design diminishes the risk of missing data and enables measurements of
75 many parameters that are relevant for this disease
- 76 - The number of participating centres ensures a quick dissemination of the results
- 77 - The absence of comparison to a placebo intervention and a study arm with patients who do
78 not undergo any intervention is a limitation of this trial

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

79 **Registration details**

80 This trial is registered in the Netherlands Trial Register (trial NL9095,
81 <https://www.trialregister.nl/trial/9095>) and in the ISRCTN registry (trial ISRCTN12074571,
82 <https://www.isrctn.com/ISRCTN12074571>).

For peer review only

83 **Introduction**

84 Ménière's disease (MD) is an incapacitating disease of recurrent vertigo attacks,
85 accompanied by hearing loss, tinnitus and/or aural fullness. Between the attacks of vertigo
86 intervals of days, weeks or even months may occur [1, 2]. The natural course of MD has
87 been studied and it has been found that the attacks of vertigo become less severe and
88 disappear after two years in 60% and after eight years in 80% of patients [3-6]. In the end
89 phase of the disease patients without vertigo attacks may still suffer from lasting hearing loss
90 and tinnitus and chronic instability caused by hypofunction of the labyrinth.

91 The disease is of idiopathic origin, but is associated with endolymphatic hydrops in the inner
92 ear [7]. Visualization of the hydrops became possible with the introduction of delayed post-
93 contrast high resolution MR imaging [8-11]. Hydrops is associated with duration of MD and
94 saccular hydrops is associated with sensorineural hearing loss [12]. Perilymphatic signal
95 intensity is a surrogate marker for impaired blood-labyrinth permeability. Signal intensity
96 (without) hydrops is markedly increased in the acute phase of labyrinthitis and is increased in
97 patients with MD [13].

98 Few articles have been published on the epidemiology of MD. Great variation exists in the
99 published reports of the prevalence of MD, ranging from 34.5 to 218 cases per 100,000 [14-
100 17]. The difference in prevalence might be due to the wide variations in definitions of MD.
101 There seems to be a slight female preponderance, with up to 1.3 times more women affected
102 than men. The disease is more common in adults in their fourth and fifth decade of life [5, 6,
103 17].

104 *Treatment options*

105 The treatment of MD both in primary and secondary care setting is focused on the reduction
106 of the frequency and intensity of vertigo attacks. Current treatments have either proven to be
107 ineffective (Betahistin [18]), only have a temporary effect (intratympanic dexamethasone
108 injections [19], or methylprednisolone [20]), or destroy the labyrinth function (intratympanic
109 gentamicin, labyrinthectomy, selective neurectomy [2, 21, 22]). Surgical destruction of the
110 labyrinth reduces the episodes of attacks but causes loss of balance as well, due to one
111 dysfunctional labyrinth. Moreover, permanent sensorineural hearing loss is reported after this
112 treatment.

113 Recently, an international guideline for the diagnostic work-up and treatment of MD was
114 published [23]. It recommends step-up treatment, starting with education of patients and
115 discussing diuretics/betahistin. Intratympanic administration of corticosteroids is considered
116 optional if patients do not respond to more conservative therapy. The last non-ablative option
117 that can be considered, is endolymphatic sac decompression. Endolymphatic sac

1
2
3 118 decompression (ESD) consists of a mastoidectomy and, after identification of the
4 119 endolymphatic sac, wide decompression of this structure [22]. ESD has few surgical
5 120 complications in comparison with the ablative surgery mentioned above. However, results
6 121 from this type of surgery are inconclusive [23].

7
8
9 122 If there is no response to non-ablative treatments, treatment with intratympanic gentamicin is
10 123 recommended, and if the disease remains unmanageable and the patient has non-usable
11 124 hearing, labyrinthectomy is advised. Patients should also be referred for vestibular
12 125 rehabilitation therapy in case of chronic balance problems, and clinicians should counsel
13 126 patients with hearing problems about hearing aids.

17 18 127 *Endolymphatic sac surgery*

19 128 Although surgery on the endolymphatic sac is briefly discussed in the guidelines, it may be
20 129 worth further investigation. The advantage of procedures targeting the endolymphatic sac is
21 130 that they are non-destructive and do therefore not affect the cochlear and vestibular function.
22 131 Apart from decompression of the sac, as is discussed in the guideline [23], shunting or
23 132 drainage of the ES has also been proposed. These techniques involve identification of the
24 133 ES, followed by incision of the sac. A shunt is then placed, enabling drainage of the
25 134 endolymph.

26 135 Several studies were directed to investigate surgery on the endolymphatic [24-26]. Bretlau
27 136 and Thomsen compared ESS to a sham operation (either mastoidectomy or placement of
28 137 ventilation tubes); no differences between the groups was observed. Brinson compared
29 138 shunting to decompression performed on 88 and 108 patients, respectively. He concluded
30 139 that both procedures are effective.

31 140 Multiple histological studies refute the rationale of endolymphatic sac surgery. Firstly, Chung
32 141 et al, performed a histopathological study 15 patients who had undergone ESS [27]. If the
33 142 endolymphatic sac does indeed have a function in resorption of the endolymph but does so
34 143 inadequately, ESS and especially ESD would allow expansion of these structures and would
35 144 therefore diminish hydrops. However, diffuse hydrops on temporal bone was seen in the
36 145 cochlea, the saccule, the utricle, and the ampulla after ESD. The authors conclude that ESD
37 146 does not relieve hydrops in patients with Ménière's disease.

38
39
40 147 In addition, if the ES was responsible for endolymph resorption, an increase of hydrops can
41 148 be expected after amputation of the ES. However, Linthicum et al. reported a case in which
42 149 removal of the ES did not lead to an increase of hydrops, as seen on temporal bone
43 150 histopathology [28]. In the assessed samples, Reissner's membrane was attached to the
44 151 spiral ligament in a normal way, without any evidence of hydrops in the cochlea. In

1
2
3 152 conclusion, the role of the ES is not merely absorption of the endolymph and therefore,
4 153 providing more space to allow dilatation is not the solution for the observed hydrops.

5
6
7 154 The success rates of these surgical interventions vary between 30-95% [2, 4, 22, 29-31]. It
8 155 should be noted that the natural course of MD is also favourable, and it cannot be
9 156 determined to what extent the outcome of procedures are due to the surgical intervention.
10 157 Moreover, the placebo effect may play a major role in the relief of complaints, as 70% of MD
11 158 patients in all groups (all surgical interventions as well as the control groups) experienced
12 159 some relief of complaints. This either implicates a beneficial effect of any surgical
13 160 intervention or of any intervention, be it surgical or non-surgical. This was earlier suggested
14 161 by Thomsen [25].

15 162 *A new technique*

16 163 Recently, a new surgical intervention has been studied by Saliba et al. [32]. A paradigm shift
17 164 for the pathophysiological model of MD underlies this new treatment. Until now it is believed
18 165 that the disease is caused by a surplus of endolymph originating in the inner ear, caused by
19 166 a disequilibrium in the production of endolymph in the inner ear and its resorption in the
20 167 endolymphatic sac [7, 33, 34]. However, Saliba et al. state that the organic substrate of the
21 168 disease - the surplus of endolymph causing the hydrops – also originates in the
22 169 endolymphatic sac.

23 170 The idea that the surplus of endolymph originates in the ES, is supported by two studies that
24 171 suggest that the ES has secretory functions as well, rather than merely a function in
25 172 absorption. In a study of the subcellular structure of the endolymphatic sac in guinea pigs by
26 173 Takumida et al., the presence of dark cells in the endolymphatic sac was shown [35]. These
27 174 cells have a secretory role. Moreover, a study performed by Friis on Lewis rats showed
28 175 hyperactivity of the cells of the endolymphatic sac, leading to an increase of endolymph
29 176 secretion [36]. In conclusion, histological evidence that the ES is –at least in part-
30 177 responsible for the endolymph surplus.

31 178 Based on these findings, Saliba's hypothesis is that in Ménière's disease, there is imbalance
32 179 in the fluid homeostasis of the endolymph at the level of the endolymphatic sac, where the
33 180 increased secretion outweighs the decreased absorption in the ES. Thus, by blocking the
34 181 endolymphatic duct, Saliba aims to decrease the volume of endolymph in the inner ear,
35 182 thereby alleviating the symptoms of Ménière's disease. This operation, referred to as the
36 183 Endolymphatic Duct Blockage (EDB), involves placing a clip on the endolymphatic duct to
37 184 separate the endolymphatic sac from the rest of the inner ear. Benefits of this technique are
38 185 its permanent nature and the fact that it does not destroy the labyrinth or inner ear function.

1
2
3 186 Saliba has performed a randomized trial to study the effect of EDB [32]. The trial compared
4 187 EDB to ESD and was conducted prospectively and non-blinded. There was no comparison to
5
6 188 a group of patients receiving placebo treatment, for instance a sham operation. The results
7
8 189 have been published in 2015 [32] and show that 34 of 35 treated patients were free of vertigo
9
10 190 attacks after EDB surgery. It is interesting to note that the efficacy for the absence of vertigo
11
12 191 attacks following ESD was only reported to be about 40% in Saliba's trial [32]. In earlier
13
14 192 studies by Bretlau and later Thomsen, percentages for both ESD and sham operations were
15
16 193 reported to be as high as 70%. Possibly, this can be explained by the open character of the
17
18 194 Saliba study, causing patients to experience the 'nocebo-effect', caused by feeling like they
19
20 195 have not been treated because they did not have the EDB surgery (but the ESD instead).
21
22 196 The fact that Saliba et al. did not assess outcomes in a double-blinded way is a flaw in
23
24 197 methodology given the high placebo effect of interventions in Ménière disease. Moreover,
25
26 198 randomisation was not stratified and there is a risk of recall bias, as it is not described how
27
28 199 vertigo bouts are recorded. Lastly, all participants were asked to follow the CATS (caffeine,
29
30 200 alcohol, theophylline and salt restricted diet. The role of this diet is not clear.

31
32 201 In a more recent publication by the group of Saliba it is reported that 43 (79%) of a group of
33
34 202 54 patients treated with EDB had an improved quality of life (QoL) [37]. The results of these
35
36 203 studies indicate that EDB may have a favourable effect on both the bouts of vertigo that MD
37
38 204 patients suffer, as on the quality of life. It should be noted that this study was at risk for recall
39
40 205 bias, as patients had to fill out questionnaire in retrospect.

41 206 *EDB pilot*

42 207 In the Netherlands, a pilot group of 34 patients underwent EDB. Quality of life was assessed
43
44 208 in 26 of these patients; in this group, a significant ($p=.001$) improvement of quality of life seen
45
46 209 [38]. Three of these patients suffered drop attacks post-operatively, but these symptoms
47
48 210 were all resolved within 8 weeks. In three patients, a postsurgical cerebrospinal fluid (CSF)
49
50 211 leakage occurred; successful surgical reintervention was performed the next day. In addition,
51
52 212 EDB surgery was performed on another group of 60 patients. No adverse events occurred in
53
54 213 this group of patients and most of the patients remained free of vertigo attacks..

55 214 According to the results discussed above, EDB is a promising surgical technique for treating
56
57 215 MD that preserves hearing and equilibrium functions. The current trial further investigates the
58
59 216 effectiveness of the EDB in treating MD, as compared to endolymphatic sac decompression.

60 217

1
2
3 218 **Methods and analysis**

4
5 219 *Participants*

6 220 Patients will be recruited in the participating centres in the Netherlands. Thirteen hospitals
7
8 221 take part in this study, five of which are academic centres. In order to include only active
9
10 222 Meniere's disease, to avoid interference with follow up and to minimize risk for the patients,
11 223 eligibility criteria apply. These can be found in **Table I**. All participants will be informed about
12
13 224 this trial by their own ENT-surgeon. Informed consent can be signed after a two week
14
15 225 reflection period. A model informed consent form can be found in Appendix 1.

16 226 Each surgeon collects the number of patients that was screened for this study in order to
17
18 227 assess generalizability of the results. This will be done in the patient records of each hospital.
19
20 228 After enrollment, data will be collected in Castor EDC. All data will be treated confidentially.

21
22 **Inclusion criteria**

23
24 Definite unilateral MD according to diagnostic criteria of the Bárány Society (Lopez-
25 Escamez, 2016)

26
27 More than 3 patient reported attacks in the 6 months prior to inclusion and at least 1
28 attack in the 2 months prior to inclusion

29
30 Non responding to a sufficient extent to conservative medical treatment including at
31 least two sessions of at least one intra-tympanic injection (IT) each with corticosteroids
32 (dexamethasone, methylprednisolone, triamcinolonacetone)

33
34 Dutch health care insurance

35
36 Age \geq 18 years at the start of the trial

37
38 **Exclusion criteria**

39
40 Severe disability (e.g. neurological, orthopaedic, cardiovascular) according to the
41 investigator, pregnancy or serious concurrent illness that might interfere with surgery
42 or follow-up.

43
44 Active additional neuro-otological disorders that may mimic MD (e.g. vestibular
45 migraine (VM), recurrent vestibulopathy, phobic postural vertigo, vertebro-basilar TIAs,
46 acoustic neuroma, congenital disorders, enlarged vestibular aqueduct (EVA)-like or
47 genetic disorders (like DFNA9), cervicogenic dizziness), based on the complete
48 clinical record.

49
50 Unable to undergo MRI (such as gadolinium allergy, claustrophobia, implanted non-
51 MRI compatible device of material, BMI)

52
53 Previous ear surgery for MD (IT injection is not an exclusion criterion)

54
55 Deafness of the contralateral ear

56
57 Language difficulties

Active otitis media (with or without effusion)
Unable or unwilling to use app-based diary

229 *Table 1. Inclusion and exclusion criteria*

230

231 *Interventions*

232 All participants will undergo surgery. Participants will be allocated in the EDB group or
 233 endolymphatic sac decompression group using an automated telephone randomised service
 234 (Castor). Participants will be stratified according to gender and duration of MD (recent-onset
 235 versus mature MD participants). A “recent-onset MD participant” is defined as having their
 236 first MD vertigo attack in the two years prior to inclusion. “Mature MD participants” have had
 237 their first MD vertigo attack more than two years prior to inclusion. By stratification for the
 238 duration of the disease, the effect of the natural course of disease on the outcome is
 239 reduced.

240 The surgeries will be performed by two surgeons. One surgeon is experienced in this
 241 intervention and will act as proctor in all surgeries carried out for this trial. The second
 242 surgeon is the ENT-surgeon who included the patients in this study. By working with only one
 243 proctor who attends all surgeries, we aim to minimize outcome heterogeneity due to surgeon
 244 specific factors.

245 The two ear surgeons will be present up to wherein the sac is completely skeletonized. Then
 246 one of the surgeons will leave the OR. The randomization for clip or decompression
 247 operation will be performed using the automated telephone randomized service. The surgeon
 248 who leaves the OR will take care of the follow up of the patient and does not know whether
 249 the clip has been placed or not.

250 *EDB surgery protocol*

251 Surgery is performed as described by Saliba [32]. First, a canal wall-up mastoidectomy is
 252 performed: the mastoid tegmen, sigmoid sinus, and sinodural angle are identified, and the
 253 posterior bony external ear canal wall is thinned. The posterior semi-circular canal (PSCC)
 254 and the dura mater of the posterior fossa are identified. Using the prominence of the
 255 horizontal semi-circular canal, Donaldson’s line is identified to approximate the position of the
 256 endolymphatic sac. The bone over the sac and the dura are thinned with diamond burrs. The
 257 sac is completely skeletonized. The infralabyrinthine dura is exposed because the main body
 258 of the sac and its lumen often lie within this area. The bone of the vestibular aqueduct
 259 operculum is dissected. The posterior fossa dura from the retrolabyrinthine bone medial to
 260 the sac around the endolymphatic duct is exposed in order to identify the duct in its superior

1
2
3 261 and inferior part in continuity from the endolymphatic sac, and to create a place to insert the
4 262 tips of the instrument to clip the duct. At this level, care must be taken not to traumatize the
5 263 dura, which is often thin.

6
7
8 264 Finally, the dissected endolymphatic duct is blocked with an adequate titanium clip (Weck
9 265 Horizon, size 'micro' to 'wide, Teleflex). The size and numbers of clips used will be
10 266 determined intraoperatively. The titanium clips are applied by using a clip applier (Weck
11 267 Horizon). If available, a CT-scan is then performed to assess clip position. In the case of
12 268 tearing of the dura leading to liquor leakage, this will be treated with tisseel, fascie and
13 269 novacol. Bone paste is collected during surgery and the cortex is restored with a mix of bone
14 270 paste, ofloxacin (3 mg/ml, Bausch&Lomb) and Tisseel (4 ml, Baxter B.V.).

20 271 *Decompression surgery protocol*

21
22 272 The same surgical procedure is carried out in the decompression group. However, after
23 273 identification of the posterior canal, and the ES will be decompressed. No clips will be
24 274 placed. The cortex is restored in the same procedure as described above.

26 275 *Expected risks of surgery*

27
28 276 Usual risk for surgery, such as infection and bleeding, apply. The main perioperative risk is
29 277 liquor leakage. In most cases, this can be solved during surgery. If the leakage occurs after
30 278 surgery, the patients will need to be operated again to repair the leak. Moreover, shortly after
31 279 surgery, benign paroxysmal positional vertigo (BPPV) may occur as a result of burring during
32 280 surgery. Other surgery-related risks are meningitis, hearing loss, facial nerve palsy and
33 281 labyrinth function loss. Meningitis and facial nerve palsy have not been reported (nor
34 282 literature nor in the patients operated in our centre).

35 283 To anticipate anatomic variation, a pre-operative CT-scan of the petrous part of the temporal
36 284 bone will be made. Moreover, an intraoperative CT-scan will be made (if available at the
37 285 operating room) just before applying of the clip in the EDB group, to assess if the clip is
38 286 placed correctly.

42 287 *Use of escape medication*

43 288 Use of any co-intervention, such as intratympanic injection of steroid or use of anti-emetics,
44 289 are allowed and will be based on the participants' experience of vertigo attack frequency and
45 290 patient-doctor preference (shared decision-making). Shared decision-making ensures wide
46 291 applicability of study results and reflects daily medical practice. *Follow up and outcome*
47 292 *measures*

48 293 From the moment of inclusion, all participants will use an app-based diary (the DizzyQuest
49 294 App [39]) in which they fill out a daily questionnaire. Attacks are also reported in this app. All
50 295 participants receive an individual tailored vestibular rehabilitation program after surgery.

1
2
3 296 Follow up visits will take place at 1 week, 3 months, 6 months and 12 months after surgery.
4 297 Which outcomes will be measured at what moment can be found in **Table II**. All data will be
5 298 stored in Castor EDC.
6
7
8 299
9

Moment in trial	Type of follow up	Outcomes
From moment of inclusion until 1 year after surgery		Daily questionnaire in app
>4 weeks before surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	Questionnaires	Baseline characteristics HADS DHI THI FLS EQ 5D VAS SF36 NPQ Assessment of expectations patient VADL VAP
	Imaging	MRI CT
1 week after surgery	Other	PTA Calorigram
	ENT-surgeon	Standard postoperative care (video-)HIT
3 months after surgery	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	ENT-surgeon	(video-)HIT
3 months after surgery	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	ENT-surgeon	(video-)HIT

	Questionnaires	DHI THI FLS EQ 5D VAS SF36 iMCQ iPCQ
	Imaging	MRI
	Other	PTA
6 months after surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	Questionnaires	DHI THI FLS E Q 5D VAS SF36 iMCQ iPCQ
	Imaging	-
	Other	PTA
12 months after surgery	ENT-surgeon	(video-)HIT
	Physiotherapy	Balance test Dynamic visual acuity Gait (DGI)
	Questionnaires	DHI THI FLS EQ 5D VAS SF36 iMCQ iPCQ

		VADL
		VAP
	Imaging	MRI
	Other	PTA Calorigram

300

301 *After follow up.*

302 When the last patient has been followed up for a year, patients can choose to be deblinded if
 303 they wish. If the patient was allocated to the EDB group but still suffers vertigo bouts, a CT-
 304 scan will be performed to assess if the clip is correctly in place. If the results of this trial are in
 305 favour of EDB, patients in the decompression group who still suffer vertigo attacks will be
 306 offered EDB. In case of a favourable outcome of EDB, a trajectory for implementation in the
 307 current Dutch health care system is also foreseen.

308 We hypothesize that the number of patients without vertigo spells at 12 months follow up will
 309 be higher in the group that has undergone EDB than in the decompression group. Secondary
 310 outcomes include minimally clinically significant differences in cumulative incidence of vertigo
 311 bouts, hearing, use of escape medication, co-interventions, complications of surgery,
 312 questionnaire outcomes, cost effectiveness analysis, budget impact analysis, endolymphatic
 313 hydrops on MRI and multiple physiotherapeutical outcomes. We hypothesize that the
 314 outcomes of these measures will be better in participants undergoing EDB compared to
 315 participants who have had a decompression operation.

316 The sample size for this RCT was computed using software package PASS 11. The sample
 317 size calculation is based on the study performed by Saliba [32], in which complete control of
 318 vertigo was reached in 96,5% of the patients who underwent EDB. According to literature,
 319 endolymphatic sac decompression is effective is $\pm 70\%$ of the patients [26, 30, 31].

320 We compare MD participants undergoing an operation with clip (EDB group: A group)
 321 independently with MD participants undergoing operation without clip (decompression group:
 322 B group). Null hypothesis is that the percentage points difference between groups
 323 percentages is nil ($p_A=p_B$), with two-sided alternative hypothesis ($p_A <> p_B$) and with
 324 anticipated 25% percent difference ($p_A= 95\%$ and $p_B = 70\%$). Power is at least 80%. The
 325 chance of a false positive finding for either of the analyses is controlled at the 5% level
 326 (family wise error rate). To obtain a power of at least 80-% for Fisher's Exact test, the
 327 required sample size is 32 in groups A and B (allocation ratio =1). Loss to follow-up will likely
 328 occur in a small percentage of cases. No selective loss to follow-up is anticipated and a
 329 missing-at-random assumption is reasonable. Missing outcomes will therefore be imputed

1
2
3 330 using multiple imputation in the main analysis. Two sensitivity analyses will be conducted as
4 331 well, where missing outcomes will be treated as failures or success, respectively. In this case
5 332 the sample size would be 42 in group A and B (allocation ratio = 1). The total number of
6 333 participants will be 84.
7
8
9

10 334 *Endolymphatic hydrops on MRI*

11 335 We hypothesize that EDB results in a decrease in hydrops and perilymph signal intensity.
12 336 These two parameters will be measured pre-operatively, as well as 3-months and 12-months
13 337 post-operatively to assess if the hydrops diminishes after EDB and is clinically relevant.
14
15
16

17 338 *Data analysis*

18 339 All collected data will be accessible for the coordinating investigator, the principal investigator
19 340 and for the investigators involved in carrying out analyses.
20
21
22

23 341 The primary outcome is defined as being attack free at 12 months follow-up. All statistical
24 342 tests will be performed two-sided at a significance (α) level of 5%. When using confidence
25 343 limits, the confidence interval will be 95%. The primary analysis will be performed following
26 344 the intention-to-treat principle. A chi-square test (or Fisher's exact test) will be performed on
27 345 the primary outcome variable data (number of patients free of vertigo attacks at 12 months
28 346 post-operatively, in EDB vs endolymphatic sac decompression group). Although
29 347 randomization is stratified, the impact of gender and duration of MD is deemed small. These
30 348 variables will only be added as covariates to the analysis if they are independently
31 349 associated with the outcome. In the case, a logistic regression will be performed.
32
33
34
35
36

37 350 The daily questionnaire taken via the DizzyQuest app is likely to contain missing data. All
38 351 other missing data will be labelled 'NAmissing' in SPSS. Multiple imputation will be used to
39 352 create complete data sets. Depending on the missing data pattern, different strategies will be
40 353 followed. Preferably, 'wide' data format will be used to account for time dependent effects. As
41 354 an alternative for larger percentages of missingness, data will be imputed in long format,
42 355 ignoring time dependent effects.
43
44
45
46

47 356 The outcome will be determined from the imputed App-data. It is expected that attacks are
48 357 reported reliably and missing data can be reliably imputed as being attack free. In principle, a
49 358 patient can be sometimes imputed as having an attack on otherwise as being attack-free. To
50 359 account for these potential cases, a cut-off of 10% for the attack probability (as the imputed
51 360 frequency for having an attack) will be used to determine presence/absence of attacks.
52
53
54

55
56 361 The Patient Reported Outcome Measures (PROMs) used in this study are assumed to be
57 362 continuous numerical and will be tested checked for near-Gaussian distribution normality
58 363 before analysis. Results will be described as means (with 95%CI) in case of near-Gaussian
59
60

1
2
3 364 distribution or, otherwise medians (with IQR) will be presented at each time point.
4 365 Categorical outcomes will be presented in numbers of participants with accompanying
5 366 percentages of group total.
6
7

8 367 All secondary outcomes will be analysed using a linear mixed model (EDB versus
9 368 decompression group) at the different time measurement point.
10
11

12 369 All the participating centres will be issued standard operating procedures (SOPs) for
13 370 procedures such as inclusion of patients, a format for follow up visits and reporting of
14 371 (serious) adverse events. With these checklists, an effort is made to improve adherence to
15 372 the protocol. The coordinating investigator will be in close contact with all the local
16 373 investigators to discuss problems experienced during recruitment and follow up.
17
18
19

20 374 Substantial protocol amendments will be reviewed by the medical ethics committee. If
21 375 approved, the amendments will be directly communicated to the local investigator of the
22 376 participating centres. Moreover, the funding party and the trial registries will be informed.
23 377 This is the responsibility of the coordinating investigator.
24
25
26
27

28 378 *Economic evaluation*

29 379 A one-year trial-based cost-effectiveness analysis (costs per prevented vertigo-attack, from a
30 380 healthcare perspective), a cost-utility analysis (costs per QALY, from a societal perspective),
31 381 and a budget-impact analysis will be performed. Societal costs will be assessed from the
32 382 patients' medical records and from patient questionnaires at 3, 6 and 12 months. QALYs will
33 383 be calculated as the area under the utility curve, estimated using the Dutch tariff for the EQ-
34 384 5D-5L at 0, 3, 6, 12 months (and the EuroQol visual analogue scale with power
35 385 transformation as secondary analysis). Average costs and patient outcome will be compared
36 386 according to intention to treat, using net benefit analysis, and multiple imputation to account
37 387 for missing data.
38
39
40
41
42
43

44 388 *Patient and public involvement*

45 389 Several patients and the patient support group for hearing and equilibrium disorders were
46 390 involved in the design of this trial. Patients have provided feedback on feasibility of the
47 391 number of questionnaires. The patient support group will also be involved in recruitment of
48 392 patients, by spreading information about the trial. During the conduct of the trial, the
49 393 frequency of questionnaires (mainly the app based diary) will be evaluated with the
50 394 participants.
51
52
53
54

55 395 The SPIRIT reporting guidelines were used for publication of this protocol [40].
56
57
58
59
60

396 **Ethics and dissemination**

397 *Ethics.*

398 The protocol was extensively reviewed by the Dutch National Health Care Institute and was
399 approved by their board (decision number 2020010440). Moreover, the protocol was
400 reviewed and approved by the Medical Research Ethics Committee Leiden The Hague Delft
401 (METC-LDD, number P20.118). The study will be conducted according to the principles of
402 the Declaration of Helsinki (October 2013) and in accordance with the Medical Research
403 Involving Human Subjects Act (WMO, 26 February 1998) and the International Conference
404 on Harmonization Good Clinical Practice (ICH GCP, November 2016). *Patient safety.*
405 A Data Safety Monitoring Board (DSMB) was established to monitor the safety of the
406 participants throughout the trial. The three members are not in any other way involved in the
407 trial and have therefore no conflict of interest with the sponsor of the study. An interim
408 analysis of the data for the first 21 participants 3 months after surgery will be performed,
409 focusing on safety of the surgical procedures. The DSMB will assess the results and discuss
410 the outcome, and give advice whether or not to continue the study. Termination of the trial
411 will be considered if there are more (serious) adverse events than expected, that are related
412 to the intervention. Moreover, monitoring of the conduct of the study will be performed,
413 according to the monitor plan that was written.

414 All serious adverse events will be reported in the official tool of the Dutch Central Committee
415 on Research Involving Human Subjects.

416 An emergency phone number will be provided to the participants, for when deblinding is
417 necessary because of a medical emergency.

418 *Dissemination*

419 The protocol will be submitted for open access publication to make it publicly available. Data
420 from the dataset will not be accessible, but can be requested. The same applies for the
421 statistical code.

422 *Results.*

423 Results of this study will be published in international peer-reviewed scientific journals and
424 will be presented on (inter)national scientific conferences and meetings. Individual centres
425 included in this multicentre trial will not report or publish data from this centre alone. Transfer
426 of ownership of the data will be reported to the appropriate authority/authorities, as required
427 by the applicable regulatory requirement(s). All publications and presentations are to protect
428 the research integrity of the participants and objectives of the study. No data will be
429 presented or released that may break the masking of the study trial. The timing of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

430 presentation and/or publications of the primary and/or secondary outcomes will be secured
431 by the supervising researchers and will be communicated first with all centres involved.

432 All data remains stored in Castor for 15 years after termination of the trial.

433

For peer review only

1
2
3 434 **List of abbreviations**
4

5	BMI	Body mass index
6		
7	CI	Confidence interval
8		
9	CSF	Cerebrospinal fluid
10		
11	CT	Computed tomography
12		
13	DGI	Dynamic gait index
14		
15	DHI	Dizziness handicap index
16		
17	DSMB	Data Safety Monitoring Board
18	EDB	Endolymphatic duct blockage
19	ENT	Ear, nose, throat
20		
21	EQ 5D	EuroQol 5D
22		
23	ES	Endolymphatic sac
24		
25	ESD	Endolymphatic sac decompression
26		
27	ESS	Endolymphatic sac surgery
28		
29	EVA	Enlarged vestibular aqueduct
30		
31	FLS	Functional level scale
32		
33	HIT	Head impulse test
34		
35	IQR	Interquartile range
36		
37	iMCQ	IMTA Medical Cost Questionnaire
38		
39	iPCQ	IMTA Productivity Cost Questionnaire
40		
41	IT	Intratympanic
42		
43	MD	Meniere's disease
44		
45	MRI	Magnetic resonance imaging
46		
47	NPQ	Niigata PPPD Questionnaire
48		
49	OR	Operating room
50		
51	PROM	Patient reported outcome measure
52		
53	PSCC	Posterior semi-circular canal
54		
55	PTA	Pure-tone average
56		
57	QALY	Quality adjusted life year
58		
59	QoL	Quality of life
60		
	RCT	Randomized controlled trial
	SF36	Short Form Health Survey 36
	THI	Tinnitus handicap index

1		
2		
3	TIA	Transient ischemic attack
4		
5	VADL	Vestibular Disorders Activities of Daily Living Scale
6		
7	VAP	Vestibular activities and participation questionnaire
8		
9	VAS	Visual analogue score
10		
11	VM	Vestibular migraine

12 435

13 436

16 437 **Authors' contributions**

18 438 All authors were involved in conception of the trial: HB, JK, PvB and AS for the clinical
19 439 aspects, SC provided epidemiological expertise, WvdH designed the economic evaluation,
20 440 SB is the trial statistician, SHa is involved for the radiological aspects and SHo is responsible
21 441 for the physiotherapeutical part of the study. Therefore, all authors contributed to writing of
22 442 the protocol. This article was drafted by AS and critically revised by all authors, who provided
23 443 feedback regarding their field of expertise and revised it for important intellectual content.
24 444 During the trial, AS is responsible for data collection, management, analysis and
25 445 interpretation. During the trial, the funder has an advisory role. Start-up of the trial will take 6
26 446 months, recruitment of participants 2 years, follow up 1 year and 6 months are provided for
27 447 analysis and interpretation of the data. Outcomes will be reported to the funder after this total
28 448 period of 4 years. Submitting of data to an international paper is the responsibility of HB and
29 449 AS. All authors read and approved of the final version of this article.

37 450

39 451 **Roles and responsibilities**

41 452 The authors of this protocol form the trial steering committee. All were engaged in study
42 453 design and will be involved in analysis, interpretation of data, writing of the report and the
43 454 decision to submit the outcomes for publication. AS is the coordinating investigator and HB is
44 455 the principal investigator and are responsible for data collection and management.

48 456

51 457 **Funding statement**

53 458 This work was supported by the 'Potentially Promising Care' subsidy from the Dutch National
54 459 Health Care Institute and ZonMw (project number 80-86200-98-19017).

56 460

59 461 **Competing interests statement**

462 None to declare.

463

464 Acknowledgements

465 The authors thank dr. Y. Smulders for her suggestion to publish the protocol.

466

467 Full references

- 468 1. Lopez-Escamez, J.A., et al., *Diagnostic criteria for Ménière's disease*. J Vestib Res, 2015. **25**(1): p. 1-7.
- 469 2. Pullens, B., H.P. Verschuur, and P.P. van Benthem, *Surgery for Ménière's disease*. Cochrane Database Syst Rev, 2013. **2013**(2): p. Cd005395.
- 470 3. Portmann, G., *The old and new in Meniere's disease -- over 60 years in retrospect and a look to the future*. Otolaryngol Clin North Am, 1980. **13**(4): p. 567-75.
- 471 4. Silverstein, H., E. Smouha, and R. Jones, *Natural history vs. surgery for Ménière's disease*. Otolaryngol Head Neck Surg, 1989. **100**(1): p. 6-16.
- 472 5. Perez-Garrigues, H., et al., *Time course of episodes of definitive vertigo in Meniere's disease*. Arch Otolaryngol Head Neck Surg, 2008. **134**(11): p. 1149-54.
- 473 6. Van Esch, B.F., et al., *Age of onset of Ménière's disease in the Netherlands: data from a specialised dizziness clinic*. J Laryngol Otol, 2016. **130**(7): p. 624-7.
- 474 7. Merchant, S.N., J.C. Adams, and J.B. Nadol, Jr., *Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops?* Otol Neurotol, 2005. **26**(1): p. 74-81.
- 475 8. Nakashima, T., et al., *Visualization of endolymphatic hydrops in patients with Meniere's disease*. Laryngoscope, 2007. **117**(3): p. 415-20.
- 476 9. Naganawa, S. and T. Nakashima, *Visualization of endolymphatic hydrops with MR imaging in patients with Ménière's disease and related pathologies: current status of its methods and clinical significance*. Jpn J Radiol, 2014. **32**(4): p. 191-204.
- 477 10. Baráth, K., et al., *Detection and grading of endolymphatic hydrops in Ménière disease using MR imaging*. AJNR Am J Neuroradiol, 2014. **35**(7): p. 1387-92.
- 478 11. van Steekelenburg, J.M., et al., *Value of Endolymphatic Hydrops and Perilymph Signal Intensity in Suspected Ménière Disease*. AJNR Am J Neuroradiol, 2020. **41**(3): p. 529-534.
- 479 12. Attyé, A., et al., *In vivo imaging of saccular hydrops in humans reflects sensorineural hearing loss rather than Meniere's disease symptoms*. Eur Radiol, 2018. **28**(7): p. 2916-2922.
- 480 13. Shi, S., P. Guo, and W. Wang, *Magnetic Resonance Imaging of Ménière's Disease After Intravenous Administration of Gadolinium*. Ann Otol Rhinol Laryngol, 2018. **127**(11): p. 777-782.
- 481 14. Shojaku, H., et al., *Epidemiologic characteristics of definite Ménière's disease in Japan. A long-term survey of Toyama and Niigata prefectures*. ORL J Otorhinolaryngol Relat Spec, 2005. **67**(5): p. 305-9.
- 482 15. Stahle, J., C. Stahle, and I.K. Arenberg, *Incidence of Ménière's disease*. Arch Otolaryngol, 1978. **104**(2): p. 99-102.
- 483 16. Wladislavosky-Waserman, P., et al., *Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980*. Laryngoscope, 1984. **94**(8): p. 1098-102.
- 484 17. Kotimäki, J., et al., *Prevalence of Meniere disease in Finland*. Laryngoscope, 1999. **109**(5): p. 748-53.
- 485 18. Adrion, C., et al., *Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind,*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 510 *randomised, placebo controlled, dose defining trial (BEMED trial)*. *Bmj*, 2016. **352**: p.
511 h6816.
- 512 19. McRackan, T.R., et al., *Intratympanic dexamethasone as a symptomatic treatment for*
513 *Ménière's disease*. *Otol Neurotol*, 2014. **35**(9): p. 1638-40.
- 514 20. Patel, M., et al., *Intratympanic methylprednisolone versus gentamicin in patients with*
515 *unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness*
516 *trial*. *Lancet*, 2016. **388**(10061): p. 2753-2762.
- 517 21. Harner, S.G., et al., *Long-term follow-up of transtympanic gentamicin for Ménière's*
518 *syndrome*. *Otol Neurotol*, 2001. **22**(2): p. 210-4.
- 519 22. Sennaroglu, L., et al., *Intratympanic dexamethasone, intratympanic gentamicin, and*
520 *endolymphatic sac surgery for intractable vertigo in Meniere's disease*. *Otolaryngol*
521 *Head Neck Surg*, 2001. **125**(5): p. 537-43.
- 522 23. Basura, G.J., et al., *Clinical Practice Guideline: Ménière's Disease*. *Otolaryngol Head*
523 *Neck Surg*, 2020. **162**(2_suppl): p. S1-s55.
- 524 24. Bretlau, P., et al., *Placebo effect in surgery for Meniere's disease: nine-year follow-*
525 *up*. *Am J Otol*, 1989. **10**(4): p. 259-61.
- 526 25. Thomsen, J., et al., *Placebo effect in surgery for Ménière's disease. A double-blind,*
527 *placebo-controlled study on endolymphatic sac shunt surgery*. *Arch Otolaryngol*,
528 1981. **107**(5): p. 271-7.
- 529 26. Brinson, G.M., D.A. Chen, and M.A. Arriaga, *Endolymphatic mastoid shunt versus*
530 *endolymphatic sac decompression for Ménière's disease*. *Otolaryngol Head Neck*
531 *Surg*, 2007. **136**(3): p. 415-21.
- 532 27. Chung, J.W., et al., *Histopathology after endolymphatic sac surgery for Ménière's*
533 *syndrome*. *Otol Neurotol*, 2011. **32**(4): p. 660-4.
- 534 28. Linthicum, F.H. and F. Santos, *Endolymphatic sac amputation without hydrops*. *Otol*
535 *Neurotol*, 2011. **32**(2): p. e12-3.
- 536 29. Huang, T.S., C.C. Lin, and Y.L. Chang, *Endolymphatic sac surgery for Meniere's*
537 *disease. A cumulative study of twelve years' experience*. *Acta Otolaryngol Suppl*,
538 1991. **485**: p. 145-54.
- 539 30. Durland, W.F., Jr., G.M. Pyle, and N.P. Connor, *Endolymphatic sac decompression*
540 *as a treatment for Meniere's disease*. *Laryngoscope*, 2005. **115**(8): p. 1454-7.
- 541 31. Convert, C., et al., *Outcome-based assessment of endolymphatic sac decompression*
542 *for Ménière's disease using the Ménière's disease outcome questionnaire: a review of*
543 *90 patients*. *Otol Neurotol*, 2006. **27**(5): p. 687-96.
- 544 32. Saliba, I., et al., *Endolymphatic duct blockage: a randomized controlled trial of a novel*
545 *surgical technique for Ménière's disease treatment*. *Otolaryngol Head Neck Surg*,
546 2015. **152**(1): p. 122-9.
- 547 33. Semaan, M.T. and C.A. Megerian, *Contemporary perspectives on the*
548 *pathophysiology of Meniere's disease: implications for treatment*. *Curr Opin*
549 *Otolaryngol Head Neck Surg*, 2010. **18**(5): p. 392-8.
- 550 34. Salt, A.N. and S.K. Plontke, *Endolymphatic hydrops: pathophysiology and*
551 *experimental models*. *Otolaryngol Clin North Am*, 2010. **43**(5): p. 971-83.
- 552 35. Takumida, M., et al., *Three-dimensional ultrastructure of the endolymphatic sac*. *Arch*
553 *Otorhinolaryngol*, 1987. **244**(2): p. 117-22.
- 554 36. Friis, M., et al., *Experimental hyperactivity of the endolymphatic sac*. *Audiol*
555 *Neurootol*, 2013. **18**(2): p. 125-33.
- 556 37. Gabra, N., et al., *Endolymphatic duct blockage: quality of life assessment of a novel*
557 *surgical technique for Ménière disease*. *Eur Arch Otorhinolaryngol*, 2016. **273**(10): p.
558 2965-73.
- 559 38. Schenck A.A., B.C.C., Kruyt J.M., Koopman J.P., Rashid R., Van Benthem P.P., Blom
560 H.M., *Outcomes of Endolymphatic Duct Blockage for Ménière's Disease: An*
561 *Observational Cohort Study*. *Am J Otolaryngol Head Neck Surg.*, 2021. **4**(5): p. 1140
562 (preprint).
- 563 39. Martin, E.C., et al., *Introducing the DizzyQuest: an app-based diary for vestibular*
564 *disorders*. *J Neurol*, 2020. **267**(Suppl 1): p. 3-14.

- 1
2
3 565 40. Chan, A.W., et al., *SPIRIT 2013 explanation and elaboration: guidance for protocols*
4 566 *of clinical trials*. BMJ, 2013. **346**: p. e7586.
5
6 567
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Proefpersoneninformatie voor deelname aan medisch-wetenschappelijk onderzoek

EDB-operatie bij de ziekte van Ménière

Officiële titel: "De effectiviteit van endolymfatische ductusblokkade versus endolymfatische saccusdecompressie bij patiënten met oncontroleerbare ziekte van Ménière."

Inleiding

Geachte heer/mevrouw,

Met deze informatiebrief willen we u vragen of u wilt meedoen aan medisch-wetenschappelijk onderzoek. Meedoen is vrijwillig. U krijgt deze brief omdat u de ziekte van Ménière heeft. U leest hier om wat voor onderzoek het gaat, wat het voor u betekent, en wat de voordelen en nadelen zijn. Het is veel informatie. Wilt u de informatie doorlezen en beslissen of u wilt meedoen? Als u wilt meedoen, kunt u het formulier invullen dat u vindt in bijlage E.

Stel uw vragen

U kunt uw beslissing nemen met de informatie die u in deze informatiebrief vindt. Daarnaast raden we u aan om dit te doen:

- Stel vragen aan de onderzoeker die u deze informatie geeft.
- Praat met uw partner, familie of vrienden over dit onderzoek.
- Stel vragen aan de onafhankelijk deskundige, dr. Van der Schroeff
- Lees de informatie op www.rijksoverheid.nl/mensenonderzoek.

1. Algemene informatie

Het HagaZiekenhuis, het Haaglanden Medisch Centrum en het Leids Universitair Medisch Centrum hebben dit onderzoek opgezet. Hieronder noemen we het HagaZiekenhuis steeds de 'opdrachtgever'. Onderzoekers (dit kunnen artsen, onderzoeksverpleegkundigen en fysiotherapeuten zijn) voeren het onderzoek uit in verschillende ziekenhuizen.

In deze informatiefolder wordt gesproken over 'de onderzoeker'. Dat is de KNO-arts die uw deelname aan deze studie regelt. Hij of zij is ook degene die bij de operatie aanwezig is en bij wie u terugkomt na de operatie. Hierover leest u meer in paragraaf 4.

Omdat niet alle KNO-artsen in Nederland meedoen met deze studie, is dit soms een andere arts dan uw eigen.

Voor dit onderzoek zijn in totaal 84 proefpersonen nodig.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

De medisch-ethische toetsingscommissie van Leiden Den Haag Delft (METC LDD) heeft dit onderzoek goedgekeurd.

2. Wat is het doel van het onderzoek?

Er is een nieuwe operatietechniek bedacht als behandeling voor de ziekte van Ménière. Die operatie heet 'Endolymfatische DuctusBlokade', afgekort EDB. In dit onderzoek bekijken we of proefpersonen na deze operatie minder duizeligheidsaanvallen hebben. We vergelijken hen met patiënten die een soortgelijke operatie krijgen, waarbij de ductus niet geblokkeerd wordt. Deze operatie heet 'endolymfatisch saccusdecompressie'. Behalve het clipje, lijken de operaties heel erg op elkaar.

In dit onderzoek zoeken we uit of EDB na 1 jaar betere resultaten geeft, dan de operatie waarbij de ductus niet geblokkeerd wordt.

3. Achtergrond van het onderzoek

In 2015 is deze nieuwe operatie voor de ziekte van Ménière bedacht. In Canada is de eerste groep patiënten geopereerd. Daar was 2 jaar na de operatie 95% van de deelnemers aanvalsvrij. Dat waren er meer dan in de controlegroep, die een andere operatie kregen. Dit onderzoek is echter niet helemaal goed uitgevoerd. Daardoor is niet zeker of de operatie echt zo goed is.

Omdat er geen zekerheid is over het effect van EDB, wordt de operatie in Nederland nog niet door de zorgverzekeraars vergoed.

Twee Nederlandse KNO-artsen hebben de operatie ook al een aantal keer uitgevoerd. Dit gebeurde in het buitenland. Ook bij deze groep waren de resultaten goed.

4. Hoe verloopt het onderzoek?

Hoelang duurt het onderzoek?

Doet u mee met het onderzoek? Dan duurt dat in totaal ongeveer 1.5 jaar.

Stap 1: bent u geschikt om mee te doen?

We willen eerst weten of u geschikt bent om mee te doen. Daarom doet de onderzoeker een aantal onderzoeken:

- De onderzoeker bespreekt uw klachten met u.
- Lichamelijk onderzoek. De onderzoeker doet een aantal simpele testjes om het evenwichtsorgaan en het gehoor te testen.
- Evenwichtsonderzoek. Hierbij wordt wat warm en koud water in uw oren gespoten.
- Een MRI-scan. Bij deze MRI-scan wordt contrastmiddel (gadolinium) gebruikt. U krijgt dit via een infuus. De scan wordt 4 uur na het infuus gemaakt. In de tussentijd mag u doen wat u wilt.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

- Een CT-scan.
- Een hoortest.

Als u dat eerder nog niet gehad heeft, krijgt u als behandeling tegen de duizeligheidsaanvallen eerst een injectie met medicatie in het oor. Deze prikjes door het trommelvlies helpen bij sommige patiënten met de ziekte van Ménière goed. Omdat dit een minder zware behandeling is dan een operatie, wordt dit altijd eerst geprobeerd. Dit is allemaal nog 'reguliere zorg' en valt niet binnen het onderzoek.

Stap 2: voorafgaand aan de operatie

Als u mee doet aan de operatie, vinden de volgende onderzoeken vóór de operatie plaats:

- Vragenlijsten. Via de email ontvangt u verschillende vragenlijsten. Het is van groot belang dat u deze allemaal voor de operatie invult.
- Fysiotherapie. U gaat langs bij de fysiotherapeut, die een aantal metingen en oefeningen met u doet.
- Bezoek aan de anesthesioloog. U krijgt een afspraak bij de anesthesioloog, die bekijkt of u fit genoeg bent voor een operatie. Dit is een standaardbezoek.
- U installeert de 'DizzyQuest App' op uw telefoon. Hier vult u dagelijks een vragenlijst in.
- Er wordt een CT-scan gemaakt.

Stap 3: de operatie

Alle patiënten die meedoen aan dit onderzoek worden geopereerd.

Voor dit onderzoek maken we 2 groepen:

- Groep 1. De mensen in deze groep krijgen een nieuwe operatietechniek, EDB. Hierbij wordt een clip geplaatst over de ductus endolymfaticus (*zie bijlage D*). Dit is een nieuwe operatietechniek. Er is nog onvoldoende bewijs dat deze operatie goed werkt.
- Groep 2. Bij deelnemers in deze groep wordt dezelfde procedure gevolgd, maar hierbij wordt géén clip geplaatst. Verder is de operatie hetzelfde. Deze techniek heet 'decompressie' omdat er bot wordt weggenomen. Hierdoor staat er minder druk op bijvoorbeeld de saccus endolymfaticus. In veel landen wordt deze operatie uitgevoerd als behandeling van de ziekte van Ménière.

In Nederland worden beide operaties op dit moment niet uitgevoerd omdat er niet voldoende bewijs is dat ze effectief zijn.

Loting bepaalt welke operatie u krijgt. U en de onderzoeker weten niet in welke groep u zit. Als het op enig moment voor uw gezondheid belangrijk is, kan dit wel worden opgezocht.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Bij de operatie zijn twee artsen aanwezig. Eén arts is uw eigen KNO-arts. De andere arts heeft ervaring met deze operaties en werkt samen met uw arts. Op het moment van loting, verlaat uw arts de operatiekamer. Zo weet hij of zij niet in welke groep u zit.

Stap 4: onderzoeken en metingen na de operatie

Voor het onderzoek is het nodig dat u 4 keer in 12 maanden naar het ziekenhuis komt. Dit is 1 week na de operatie, en 3, 6 en 12 maanden na de operatie. Een bezoek duurt een half uur tot een uur.

We doen dan de volgende onderzoeken:

- We doen een lichamelijk onderzoek – bij alle bezoeken.
- Er wordt een MRI-scan gemaakt – 3 en 12 maanden na de operatie. Bij deze MRI-scans wordt contrastmiddel (gadolinium) gebruikt. U krijgt dit via een infuus. De scan wordt 4 uur na het infuus gemaakt. In de tussentijd mag u doen wat u wilt.
- Er wordt een hoortest gedaan – 3, 6 en 12 maanden na de operatie.
- Er wordt een evenwichtsonderzoek gedaan – 12 maanden na de operatie.
- Na elk bezoek krijgt u via de mail vragenlijsten. Deze vragenlijsten gaan over algemeen functioneren, duizeligheid en oorsuizen. Het invullen kost in totaal ongeveer een uur.

Daarnaast gaat de fysiotherapeut u behandelen. Na de operatie komt u 7 keer bij de fysiotherapeut. De fysiotherapeut doet metingen en oefeningen met u. Ook krijgt u oefeningen mee die u thuis moet doen.

Tot 1 jaar na de operatie vult u elke dag een vragenlijst in de DizzyQuest App in. Het invullen duurt 5 tot 10 minuten. De vragen gaan over uw functioneren op die dag.

Als ook de laatste proefpersoon 1 jaar lang gevolgd is, kunt u ervoor kiezen te horen in welke groep u zit. Als blijkt dat u in de EBD-groep zat, en u heeft nog aanvallen, dan kunt u een CT-scan krijgen om te zien of de clip goed zit.

In bijlage C staat uitgebreid beschreven welke handelingen, tests en onderzoeken er bij elk van die bezoeken plaatsvinden.

Wat is er anders dan bij gewone zorg?

Het eerste bezoek aan de polikliniek is 'reguliere zorg'. Hiervoor moet u dus mogelijk eigen risico betalen.

Als u in aanmerking komt om mee te doen aan het onderzoek, worden alle bezoeken en onderzoeken betaald door het onderzoek. Hier hoeft u dus geen eigen risico voor te betalen.

Niet alle KNO-artsen in Nederland doen mee aan dit onderzoek. Het kan dus zijn dat u, vanwege deelname aan het onderzoek, zal worden behandeld door een andere KNO-arts dan uw vaste KNO-arts.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Ook kan zijn dat u voor sommige onderzoeken of behandelingen naar een ander ziekenhuis moet. Dit heeft te maken met de aanwezigheid van instrumenten en de opleiding van de zorgverleners.

5. Welke afspraken maken we met u?

Om het onderzoek goed te laten verlopen, is het belangrijk dat u zich aan de volgende afspraken houdt.

De afspraken zijn dat u:

- Indien u betahistine of cinnarizine gebruikt, deze vanaf 24 uur vóór de operatie niet meer neemt.
- Afspraken voor bezoeken nakomt.
- Niet aan een ander medisch-wetenschappelijk onderzoek meedoet.
- De vragenlijst in de DizzyQuest App dagelijks invult. Dit is van zeer groot belang. Of u de app invult, wordt gecontroleerd door de coördinerend onderzoeker. Indien blijkt dat u regelmatig vergeet de lijst in te vullen, neemt zij telefonisch contact met u op.
- De vragenlijsten via de email invult.
- De oefeningen van de fysiotherapie thuis volgens schema uitvoert.
- U krijgt een deelnamekaart, waarin staat dat u deelneemt aan dit onderzoek. Indien er een scan van uw hoofd gemaakt wordt (buiten het onderzoek om), is het van belang dat u aan de arts die de scan afspreekt, vertelt dat u meedoet met dit onderzoek en dit kaartje laat zien.

Het is belangrijk dat u contact opneemt met de onderzoeker:

- Als u in een ziekenhuis wordt opgenomen of behandeld.
- Als u plotseling gezondheidsklachten krijgt.
- Als u niet meer wilt meedoen aan het onderzoek.
- Als uw contactgegevens wijzigen.

Zwangerschap

Vrouwen die zwanger zijn, kunnen niet meedoen aan dit onderzoek. Ook mogen vrouwen niet zwanger worden tijdens het onderzoek. Dit is omdat narcose niet veilig is voor een zwangerschap. Daarnaast wordt tijdens het onderzoek een CT-scan gemaakt. De straling is een risico voor het kind.

Wordt u tijdens het onderzoek toch zwanger? Laat dit dan direct weten aan de onderzoeker. U moet dan in overleg met de onderzoeker zo snel mogelijk stoppen met dit onderzoek.

6. Van welke bijwerkingen, nadelige effecten of ongemakken kunt u last krijgen?

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Er kunnen bijwerkingen en complicaties voorkomen bij beide operaties. De volgende bijwerkingen zijn bekend:

- Pijn achter het oor.
- Tijdelijke misselijkheid.
- Tijdelijke duizeligheid.
- Tijdelijk (bescheiden) gehoorverlies.

Complicaties van de operaties kunnen zijn:

- Schade aan de aangezichtsenuw. Tot nu toe gebeurt dit bij minder dan 1% van de patiënten.
- Schade aan het evenwichtsorgaan.
- Lekkage van hersenvocht.
- Ontsteking van de hersenen (meningitis).
- Tijdelijke positieduizeligheid (BPPD).
- Gehoorverlies. Dit komt voor bij minder dan 4% van de patiënten.

7. Wat zijn de voordelen en de nadelen als u meedoet aan het onderzoek?

Meedoen aan het onderzoek kan voordelen en nadelen hebben. Hieronder zetten we ze op een rij. Denk hier goed over na, en praat erover met anderen.

De operaties kunnen het aantal Ménière-aanvallen verminderen, maar zeker is dat niet. Op elk moment tijdens dit onderzoek kunnen de aanvallen terugkomen of verergeren.

Meedoen aan het onderzoek kan deze nadelen hebben:

- Mogelijke bijwerkingen en complicaties van de operatie
- Mogelijke ongemakken van de metingen in het onderzoek. U kunt bijvoorbeeld duizelig worden tijdens het evenwichtsonderzoek

Deelname aan het onderzoek betekent ook:

- Dat u extra tijd kwijt bent;
- Extra testen en onderzoeken;
- Dat u afspraken heeft waaraan u zich moet houden;

Wat zijn de nadelen van onderzoeken die gebruik maken van straling?

Bij de CT-scan voor de operatie gebruiken we röntgenstraling. U krijgt 1 of 3 CT-scans. Dit hangt af van in welke groep u zit.

Een CT-scan geeft ongeveer 2 mSv stralingsbelasting. Ter vergelijking: de achtergrondstraling in Nederland is ~2,5 mSv per jaar.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Het kan geen kwaad als u voor een medische reden een onderzoek of behandeling met straling moet ondergaan.

- Krijgt u vaker een onderzoek met straling? Bespreek dan met de onderzoeker of het verstandig is dat u meedoet.
- De straling die we tijdens het onderzoek gebruiken kan leiden tot schade aan uw gezondheid. Maar dit is een klein risico. Wel adviseren we u de komende tijd niet nog een keer mee te doen aan een wetenschappelijk onderzoek met straling.

Het is mogelijk dat u voor een ander medisch probleem een scan van het hoofd moet krijgen. Dat is geen probleem voor het onderzoek. Het clipje dat gebruikt wordt in dit onderzoek, kan zonder problemen in de MRI- of CT-scan.

Wel is het belangrijk dat u aan de arts die de scan met u afspreekt, vertelt dat u meedoet aan dit onderzoek. U kunt dan het zakkaartje laten zien. Daarop staat dat er geen bezwaar is om een scan te ondergaan, maar vragen wij de radioloog niks te zeggen over een eventuele clip. Dit is om te zorgen dat u niet weet in welke groep u zit. De radioloog schrijft in het verslag van de scan op dat er gekeken is of er een clip gezien is, maar dat daar vanwege het onderzoek niks over in het verslag opgeschreven wordt.

Het is mogelijk dat er op de CT-scan of MRI-scan toevallig iets wordt ontdekt dat niet direct van belang is voor het onderzoek maar wel voor uw gezondheid of die van uw familieleden. In dit geval zal uw eigen huisarts of specialist met u bespreken wat er verder moet gebeuren. De kosten hiervan vallen onder uw eigen zorgverzekering.

Wilt u niet meedoen?

U beslist zelf of u meedoet aan het onderzoek. Wilt u niet meedoen? Dan krijgt u de gewone behandeling voor de ziekte van Ménière. Uw arts kan u meer vertellen over de behandelingsmogelijkheden die er zijn. En over de voor- en nadelen daarvan.

8. Wanneer stopt het onderzoek?

De onderzoeker laat het u weten als er nieuwe informatie over het onderzoek komt die belangrijk voor u is. De onderzoeker vraagt u daarna of u blijft meedoen.

In deze situaties stopt voor u het onderzoek:

- Alle onderzoeken volgens het schema zijn voorbij.
- Het einde van het hele onderzoek is bereikt, dus als er 84 mensen zijn geopereerd en zij allemaal een jaar lang gevolgd zijn.
- U bent zwanger geworden.
- U wilt zelf stoppen met het onderzoek. Dat mag op ieder moment. Meld dit dan meteen bij de onderzoeker. U hoeft er niet bij te vertellen waarom u stopt. U krijgt dan weer de gewone behandeling voor de ziekte van Ménière. De onderzoeker kan voor uw veiligheid nog een of meer controles afspreken.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

- De onderzoeker vindt het beter voor u om te stoppen. De onderzoeker zal u nog wel uitnodigen voor een nacontrole.
- Een van de volgende instanties besluit dat het onderzoek moet stoppen:
 - Het HagaZiekenhuis, of
 - Het Zorginstituut Nederland, of
 - de overheid, of
 - de medisch-ethische commissie die het onderzoek beoordeelt.

Wat gebeurt er als u stopt met het onderzoek?

Als u niet meer mee wil doen met het onderzoek, mag u dat op elk moment aangeven. U hoeft niet uit te leggen waarom u niet meer mee wil doen. U kunt dit melden bij uw eigen KNO-arts; hij/zij zal contact opnemen met de coördinerend onderzoeker om dit te melden. De onderzoekers gebruiken de gegevens die tot het moment van stoppen zijn verzameld.

Het hele onderzoek is afgelopen als alle deelnemers klaar zijn.

9. Wat gebeurt er na het onderzoek?*Krijgt u de resultaten van het onderzoek?*

Ongeveer 1.5 jaar na uw deelname laat de onderzoeker u weten wat de belangrijkste uitkomsten zijn van het onderzoek. De onderzoeker kan u ook vertellen in welke groep u zat, dus welke operatie u gehad heeft. Wilt u dit niet weten? Zeg dat dan tegen de onderzoeker. Hij of zij zal het u dan niet vertellen.

Het kan zijn dat blijkt dat de EDB-operatie beter werkte. Als u niet in de EDB-groep zat, en nog wel aanvallen heeft, kunt u alsnog de EDB-operatie krijgen.

10. Wat doen we met uw gegevens?

Doet u mee met het onderzoek? Dan geeft u ook toestemming om uw gegevens te verzamelen, gebruiken en bewaren.

Welke gegevens bewaren we?

We bewaren deze gegevens:

- uw naam
- uw geslacht
- uw adres
- uw geboortedatum
- gegevens over uw gezondheid
- (medische) gegevens die we tijdens het onderzoek verzamelen

Waarom verzamelen, gebruiken en bewaren we uw gegevens?

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

We verzamelen, gebruiken en bewaren uw gegevens om de vragen van dit onderzoek te kunnen beantwoorden. En om de resultaten te kunnen publiceren. De gegevens worden verzameld in Castor, een online omgeving voor onderzoekers.

Hoe beschermen we uw privacy?

Om uw privacy te beschermen geven wij uw gegevens een code. Op al uw gegevens zetten we alleen deze code. De sleutel van de code bewaren we op een beveiligde plek in het ziekenhuis waar u behandeld wordt. Als we uw gegevens verwerken, gebruiken we steeds alleen die code. Ook in rapporten en publicaties over het onderzoek kan niemand terughalen dat het over u ging.

De gegevens die in de DizzyQuest App worden verzameld, zijn ook niet gekoppeld aan uw naam. In de app staat alleen uw deelnemerscode. De personen die de ingevulde gegevens in de app kunnen zien, zijn:

- De coördinerend onderzoeker. Zij bekijkt of u de app invult.
- De maker van de app. Hij kan gegevens inzien voor kwaliteits- en veiligheidsdoeleinden. Hij kan geen gegevens zien die naar u zijn te herleiden.
- Een onafhankelijk arts heeft toegang tot de database. Deze arts zal niet inloggen, tenzij de coördinerend onderzoeker onverwachts niet meer in staat is het onderzoek uit te voeren. Deze arts kan dan de toegang en verantwoordelijkheden overdragen aan een nieuwe coördinerend onderzoeker.

Er wordt bijgehouden en gecontroleerd wie de gegevens van de app opent en inziet.

Wie kunnen uw gegevens zien?

Sommige personen kunnen wel uw naam en andere persoonlijke gegevens zonder code inzien. Dit zijn mensen die controleren of de onderzoekers het onderzoek goed en betrouwbaar uitvoeren. Deze personen kunnen bij uw gegevens komen:

- Leden van de commissie die de veiligheid van het onderzoek in de gaten houdt.
- Een controleur die door het HagaZiekenhuis is ingehuurd of voor het HagaZiekenhuis werkt.
- Nationale toezichthoudende autoriteiten namelijk Inspectie Gezondheidszorg en Jeugd.

Deze personen houden uw gegevens geheim. Wij vragen u voor deze inzage toestemming te geven.

Hoelang bewaren we uw gegevens en lichaamsmateriaal?

We bewaren uw gegevens 15 jaar in Castor. Dit is de online omgeving waar alle gegevens worden opgeslagen.

Mogen we uw gegevens gebruiken voor ander onderzoek?

Uw gegevens kunnen na afloop van dit onderzoek ook nog van belang zijn voor ander wetenschappelijk onderzoek op het gebied van de ziekte van Ménière. Daarvoor zullen uw gegevens 15 jaar worden bewaard in Castor. In het toestemmingformulier geeft u aan of u dit

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

goed vindt. Geeft u geen toestemming? Dan kunt u nog steeds meedoen met dit onderzoek. U krijgt dezelfde zorg.

Wat gebeurt er bij onverwachte ontdekkingen?

Tijdens het onderzoek kunnen we toevallig iets vinden dat belangrijk is voor uw gezondheid. De onderzoeker neemt dan contact op met uw eigen KNO-arts. U bespreekt dan met uw specialist wat er moet gebeuren. U geeft met het formulier toestemming voor het informeren van uw specialist.

Kunt u uw toestemming voor het gebruik van uw gegevens weer intrekken?

U kunt uw toestemming voor het gebruik van uw gegevens op ieder moment intrekken. Dit geldt voor het gebruik in dit onderzoek en voor het gebruik in ander onderzoek. Maar let op: trekt u uw toestemming in, en hebben onderzoekers dan al gegevens verzameld voor een onderzoek? Dan mogen zij deze gegevens nog wel gebruiken.

Wilt u meer weten over uw privacy?

- Wilt u meer weten over uw rechten bij de verwerking van persoonsgegevens? Kijk dan op www.autoriteitpersoonsgegevens.nl.
- Heeft u vragen over uw rechten? Of heeft u een klacht over de verwerking van uw persoonsgegevens? Neem dan contact op met degene die verantwoordelijk is voor de verwerking van uw persoonsgegevens. Voor uw onderzoek is dat:
 - Het HagaZiekenhuis. Zie bijlage A voor contactgegevens, en website.
- Als u klachten heeft over de verwerking van uw persoonsgegevens, raden we u aan om deze eerst te bespreken met het onderzoeksteam. U kunt ook naar de Functionaris Gegevensbescherming van het HagaZiekenhuis gaan. Of u dient een klacht in bij de Autoriteit Persoonsgegevens.

Waar vindt u meer informatie over het onderzoek?

Op de volgende website(s) vindt u meer informatie over het onderzoek.

<https://www.hagaziekenhuis.nl/meniere>

<https://www.trialregister.nl/trial/9095> (Let op: deze website is in het Engels). Na het onderzoek kan de website een samenvatting van de resultaten van dit onderzoek tonen.

11. Krijgt u een vergoeding als u meedoet aan het onderzoek?

De **extra** ziekenhuisbezoeken, onderzoeken en de operatie voor het onderzoek kosten u niets. U krijgt geen vergoeding als u meedoet aan dit onderzoek. Wel krijgt u een vergoeding voor uw (extra) reiskosten. De gemaakte reiskosten worden aan het eind van uw deelname aan u vergoed. U dient altijd kopieën te maken van de parkeerkaartjes en/of ov-bewijzen. Voor het berekenen van de reiskosten gebruiken wij de ANWB-routeplanner en rekenen wij €0,19 per kilometer. Voor het berekenen van kosten van het openbaar vervoer gebruiken wij OV9292.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

12. Bent u verzekerd tijdens het onderzoek?

Voor iedereen die meedoet aan dit onderzoek is een verzekering afgesloten. De verzekering betaalt voor schade door het onderzoek. Maar niet voor alle schade. In **bijlage B** vindt u meer informatie over de verzekering en de uitzonderingen. Daar staat ook aan wie u schade kunt melden.

13. We informeren uw huisarts

De onderzoeker stuurt uw huisarts een brief om te laten weten dat u meedoet aan het onderzoek. Dit is voor uw eigen veiligheid.

14. Heeft u vragen?

Bij vragen kunt u contact opnemen met arts-onderzoeker Jet Schenck via duizeligheid@hagaziekenhuis.nl. Wilt u advies van iemand die geen belang heeft bij het onderzoek? Neem dan contact op met professor dr. Bruintjes, KNO-arts. Hij weet veel over het onderzoek, maar werkt niet mee aan dit onderzoek.

Heeft u een klacht? Bespreek dit dan met de onderzoeker of de arts die u behandelt. Wilt u dit liever niet? Ga dan naar de klachtenfunctionaris van uw eigen ziekenhuis. In bijlage A staat waar u die kunt vinden.

15. Ondertekening toestemmingsformulier

U kunt eerst rustig nadenken over dit onderzoek. Binnen twee weken vertelt u de onderzoeker of u de informatie begrijpt en of u wel of niet wilt meedoen. Wilt u meedoen? Dan vult u het toestemmingsformulier in dat u bij deze informatiebrief vindt. U en de onderzoeker krijgen allebei een getekende versie van deze toestemmingsverklaring.

Dank voor uw tijd.

[Lokale hoofdonderzoeker], [lokaal ziekenhuis]

Het onderzoeksteam:

- Drs. A.A. Schenck, arts-onderzoeker KNO-heelkunde, HagaZiekenhuis, Den Haag
- Dr. H. Blom, KNO-arts, HagaZiekenhuis, Den Haag
- Drs. J.M. Kruyt, KNO-arts, Haaglanden Medisch Centrum, Den Haag
- Prof. dr. P.P. van Benthem, afdelingshoofd KNO, LUMC, Leiden

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

16. Bijlagen bij deze informatie

Bijlage A.	Contactgegevens
Bijlage B.	Informatie over de verzekering
Bijlage C.	Schema bezoeken en metingen
Bijlage D.	Uitgebreide informatie over de operaties
Bijlage E.	Toestemmingsformulier(en)

For peer review only

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Bijlage A: contactgegevens voor [naam deelnemend centrum]

[Onderzoeker]: [Naam, contactgegevens en bereikbaarheid]

Onafhankelijk arts: dr. Van der Schroeff, KNO-arts Erasmus Medisch Centrum Rotterdam

Telefoon: (010) 703 60 73

Klachten: [dienst of persoon met contactgegevens en bereikbaarheid]

Functionaris voor de Gegevensbescherming van de instelling:

Voor meer informatie over uw rechten: [Contactgegevens [inclusief website] van de verantwoordelijke(n) voor de verwerking van persoonsgegevens]:

Coördinerend onderzoeker

Drs. A.A. Schenck

Afdeling KNO-heelkunde, HagaZiekenhuis, Den Haag

Email: duizeligheid@hagaziekenhuis.nl

Telefoon: 070 210 2602

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Bijlage B: informatie over de verzekering

Het HagaZiekenhuis heeft een verzekering afgesloten voor iedereen die meedoet aan het onderzoek. De verzekering betaalt de schade die u heeft doordat u aan het onderzoek meedeed. Het gaat om schade die u krijgt tijdens het onderzoek, of binnen 4 jaar na het onderzoek. U moet schade binnen 4 jaar melden bij de verzekeraar.

Heeft u schade door het onderzoek? Meld dit dan telefonisch bij deze verzekeraar:

De verzekeraar van het onderzoek is:

Naam: CentraMed
Adres: Postbus 7374, 2701 AJ Zoetermeer
Telefoonnummer: 070 301 70 70
E-mail: info@centramed.nl
(Polisnummer: 624.100.025)

De verzekering betaalt maximaal € 650.000 per proefpersoon en € 5.000.000 voor het hele onderzoek (en € 7.500.000 per jaar voor alle onderzoeken van dezelfde opdrachtgever).

Let op: de verzekering dekt de volgende schade **niet**:

- Schade door een risico waarover we u informatie hebben gegeven in deze brief. Maar dit geldt niet als het risico groter bleek te zijn dan we van tevoren dachten. Of als het risico heel onwaarschijnlijk was.
- Schade aan uw gezondheid die ook zou zijn ontstaan als u niet aan het onderzoek had meegedaan.
- Schade die ontstaat doordat u aanwijzingen of instructies niet of niet goed opvolgde.
- Schade aan de gezondheid van uw kinderen of kleinkinderen.
- Schade door een behandelmethode die al bestaat. Of door onderzoek naar een behandelmethode die al bestaat.

Deze bepalingen staan in het 'Besluit verplichte verzekering bij medisch-wetenschappelijk onderzoek met mensen 2015'. Dit besluit staat in de Wettenbank van de overheid (<https://wetten.overheid.nl>).

Bijlage C – Overzicht bezoeken en metingen

Voorafgaand aan het onderzoek

Als u gaat deelnemen aan de studie, vult u met uw arts uw toestemmingsformulier in.

Daarnaast worden de volgende metingen uitgevoerd:

- Head impulse test (vHIT). Hierbij houdt de onderzoeker met beide handen uw hoofd vast, en vraagt hij u om naar de neuspunt van de onderzoeker te kijken. Met een korte en snelle beweging wordt uw hoofd horizontaal naar rechts en vervolgens naar links gedraaid. De onderzoeker kijkt hierbij naar uw oogbewegingen.
- Hoortest
- CT-scan
- Een evenwichtsonderzoek waarbij koud en warm water in uw oor gespoten wordt

Ook ontvangt u de volgende vragenlijsten via de email:

- Hospital Anxiety and Depression Scale (HADS)
- Dizziness Handicap Inventaris (DHI): een algemene vragenlijst over duizeligheid
- Tinnitus Handicap Inventaris (THI): een algemene vragenlijst over oorsuizen
- Functional Level Scale (FLS): schaalverdeling waarin u kunt aangeven hoe u vindt dat u dagelijks functioneert
- EQ-5D: 5 vragen en een schaalverdeling waarmee u kunt aangeven hoe u uw gezondheidstoestand ervaart.
- SF-36: waarmee u uw mogelijkheden van functioneren in dagelijks activiteiten, vrijetijd en werk kan aangeven.
- NPQ: dit is een vragenlijst over duizeligheid
- VAP: dit is een vragenlijst over de last van duizeligheid in uw dagelijks functioneren
- VADL: ook deze vragenlijst gaat over last van duizeligheid in uw dagelijks functioneren
- Een vragenlijst over uw verwachtingen van het onderzoek

Tot slot komt u vlak voor de operatie langs bij de anesthesioloog voor standaard onderzoek.

Hier beoordeelt de anesthesioloog of u fit genoeg bent voor een operatie.

1 week na de operatie

- Controleafspraak bij uw KNO-arts
- Lichamelijk onderzoek
- Bezoek fysiotherapeut voor metingen en oefeningen

In de daaropvolgende weken

- In totaal 3 afspraken bij de fysiotherapeut. Die doet steeds oefeningen met u en voert metingen uit.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

3 maanden na de operatie

U komt weer terug bij de KNO-arts. Dan worden de volgende tests gedaan:

- Lichamelijk onderzoek
- MRI-scan. Bij deze MRI-scans wordt contrastmiddel (gadolinium) gebruikt. U krijgt dit via een infuus. De scan wordt 4 uur na het infuus gemaakt. In de tussentijd mag u doen wat u wilt.
- Hoortest

Ook krijgt u de volgende vragenlijsten via de email:

- DHI
- THI
- FLS
- EQ-5D
- VAS
- SF-36
- iMCQ: deze vraagt uit hoeveel zorg u gehad heeft (aantal polikliniekbezoeken, onverwachte opnames)
- iPCQ: deze vraagt uit hoe 'productief' u bent geweest, dus of/hoeveel u heeft kunnen werken.
- Bezoek fysiotherapie voor metingen en het afronden van de behandeling.

6 maanden na de operatie

U komt weer terug bij de KNO-arts. Dan worden de volgende tests gedaan:

- Lichamelijk onderzoek
- Hoortest

Ook krijgt u de volgende vragenlijsten via de email:

- DHI
- THI
- FLS
- EQ-5D
- VAS
- SF-36
- iMCQ
- iPCQ
- Bezoek fysiotherapie voor metingen

12 maanden na de operatie

U komt weer terug bij de KNO-arts. Dan worden de volgende tests gedaan:

- Lichamelijk onderzoek
- MRI-scan. Bij deze MRI-scans wordt contrastmiddel (gadolinium) gebruikt. U krijgt dit via een infuus. De scan wordt 4 uur na het infuus gemaakt. In de tussentijd mag u doen wat u wilt.
- Hoortest
- Een evenwichtsonderzoek

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Ook krijgt u de volgende vragenlijsten via de email:


- DHI
 - THI
 - FLS
 - EQ-5D
 - VAS
 - SF-36
 - NPQ
 - iMCQ
 - iPCQ
 - VAP
 - VADL
- Bezoek fysiotherapie voor metingen
 - Als blijkt dat u in de EDB-groep zat, krijgt u ook een CT-scan om te controleren of het clipje goed zit.

Bijlage D – Uitgebreide informatie over de operaties

In dit onderzoek worden twee verschillende operaties uitgevoerd. Deze operaties lijken op elkaar, maar zijn niet exact hetzelfde. In deze bijlage kunt u meer informatie vinden over de operaties.

Anatomie van het oor

Ten eerste leggen wij u de anatomie van het oor uit. Hieronder ziet u een plaatje van het rechteroor, alsof u iemand van voren aankijkt.



Figuur 1. Het oor. Bron: Leerschool audicien

A is de oorschelp en B de gehoorgang. De gehoorgang eindigt bij het trommelvlies (C). Geluid is een luchtrilling, het trommelvlies geeft die trillingen via de gehoorbeentjes (D) door naar het binnenoor.

Het binnenoor bestaat uit het evenwichtsorgaan (E) en het slakkenhuis (F).

Het evenwichtsorgaan (E) bestaat uit drie halfcirkelvormige kanalen die bewegingen meten. Die kanalen meten allemaal een nét andere beweging. Het ene halfcirkelvormige kanaal meten bijvoorbeeld hoofdbewegingen van boven naar beneden, zoals bij ja schudden. Een van de andere meet bijvoorbeeld nee schudden. De bewegingen worden omgezet in elektrisch signaal, dat via de zenuw (G) naar de hersenen wordt doorgegeven.

Het slakkenhuis (F) verwerkt geluiden. Trillingen die via het trommelvlies (C) en de gehoorbeentjes (D) in het binnenoor terechtkomen, worden in het slakkenhuis omgezet in elektrisch signaal. Ook dat signaal wordt via de zenuw (G) naar de hersenen gestuurd.


Al deze structuren liggen in de schedel (H).

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Het binnenoor

We kijken nu beter naar het binnenoor, waar het evenwichtsorgaan (E) en het slakkenhuis (F) onderdeel van uitmaken.



Figuur 2. Het binnenoor. Bron en copyright: L. de Pont.

Op Figuur 2 kunt u de halfcirkelvormige kanalen weer herkennen. Het slakkenhuis is ook afgebeeld, maar dan door de helft.

Op deze afbeeldingen staat een aantal structuren dat van belang is voor de ziekte van Ménière. Ten eerste de 'ductus endolymphaticus'. Dat is een uitloper van het evenwichtsorgaan, waar de halfcirkelvormige kanalen samenkomen. Aan het eind van de ductus endolymphaticus bevindt zich de 'saccus endolymphaticus'. Tussen de saccus endolymphaticus, het slakkenhuis en de halfcirkelvormige kanalen stroomt vloeistof: 'endolymfe'. Het endolymfe zorgt ervoor dat geluidsgolven goed worden voortgeleid en dat er signalen kunnen worden opgewekt in het evenwichtsorgaan en het gehoorsorgaan. Die signalen zorgen ervoor dat wij geluid horen en beweging kunnen voelen.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Bij de ziekte van Ménière is er te veel endolymfe, zowel in het slakkenhuis als in het evenwichtsorgaan. Hierdoor zijn er symptomen van zowel het gehoor (oorsuizen, gehoorverlies) als van het evenwicht (de draaiduizeligheidsaanvallen).

Na een aanval kan het binnenoor zich een beetje herstellen, maar omdat de druk eigenlijk de hele tijd te hoog is, wordt dat steeds moeilijker. Daarom worden de problemen met gehoor en evenwicht met de tijd steeds groter.

Het is dus van belang om te zorgen dat die druk niet te hoog wordt. Momenteel is er een operatie die zorgt dat de saccus endolymfaticus meer ruimte krijgt. Daarvoor wordt wat bot van de schedel rondom deze saccus, voorzichtig weggeboord. Dit wordt ook wel 'endolymphatic sac decompression', ofwel drukvermindering van de saccus endolymfaticus, genoemd. Hierbij hebben de saccus en ductus endolymfaticus meer ruimte om uit te zetten, wanneer er teveel endolymfe (de vloeistof in het binnenoor) is.

Deze operatie wordt in een aantal landen uitgevoerd, waaronder in Canada en Amerika. In Nederland wordt deze operatie niet uitgevoerd, omdat er niet voldoende bewijs is dat hij goed werkt.

Naast deze techniek, is er nu een nieuwe operatie bedacht. Deze heet 'endolymphatic duct blockage', ofwel blokkade van de ductus endolymfaticus. Het wordt afgekort tot EDB. Ook hierbij wordt ruimte vrijgemaakt rondom de saccus en ductus endolymfaticus. Bij EDB wordt de ductus endolymfaticus daarna afgesloten met een clipje. Dit clipje is ook te zien op Figuur 2. Dat maakt deze nieuwe operatie anders de decompressie-techniek. Hierdoor is er geen vochtuitwisseling tussen de saccus endolymfaticus en het binnenoor mogelijk. Hierdoor ontstaat er geen vochtoverschot in het binnenoor, waardoor de Ménière-aanvallen waarschijnlijk wegblijven.

In deze studie wordt EDB vergeleken met de saccusdecompressie. Zoals hierboven beschreven staat, lijken deze operaties op elkaar. Bij EDB wordt echter na het 'decomprimeren' nog een clip geplaatst.

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Bijlage E: toestemmingsformulier proefpersoon

Behorende bij

EDB bij de ziekte van Ménière

- Ik heb de informatiebrief gelezen. Ook kon ik vragen stellen. Mijn vragen zijn goed genoeg beantwoord. Ik had genoeg tijd om te beslissen of ik meedoe.
- Ik weet dat meedoen vrijwillig is. Ook weet ik dat ik op ieder moment kan beslissen om toch niet mee te doen met het onderzoek. Of om ermee te stoppen. Ik hoef dan niet te zeggen waarom ik wil stoppen.
- Ik geef de onderzoeker toestemming om mijn huisarts te laten weten dat ik meedoe aan dit onderzoek.
- Ik geef de onderzoeker toestemming om mijn huisarts of specialist informatie te geven over onverwachte bevindingen uit het onderzoek die van belang zijn voor mijn gezondheid.
- Ik geef de onderzoekers toestemming om mijn gegevens te verzamelen en gebruiken. De onderzoekers doen dit alleen om de onderzoeksvraag van dit onderzoek te beantwoorden.
- Ik weet dat voor de controle van het onderzoek sommige mensen al mijn gegevens kunnen inzien. Die mensen staan in deze informatiebrief. Ik geef deze mensen toestemming om mijn gegevens in te zien voor deze controle.
- Ik weet dat ik niet zwanger mag worden tijdens het onderzoek.
- De onderzoeker heeft met mij besproken hoe ik het beste voorkom dat ik zwanger word.
- Wilt u in de tabel hieronder ja of nee aankruisen?

Ik geef toestemming om mijn gegevens te bewaren om dit te gebruiken voor ander onderzoek, zoals in de informatiebrief staat.	Ja <input type="checkbox"/>	Nee <input type="checkbox"/>
Ik geef toestemming om mij eventueel na dit onderzoek te vragen of ik wil meedoen met een vervolgonderzoek.	Ja <input type="checkbox"/>	Nee <input type="checkbox"/>
Ik geef de onderzoekers toestemming om na het onderzoek te laten weten welke behandeling ik heb gehad/ in welke groep ik zat.	Ja <input type="checkbox"/>	Nee <input type="checkbox"/>

- Ik wil meedoen aan dit onderzoek.

Mijn naam is (proefpersoon):

Handtekening:

Datum : __ / __ / __

Proefpersoneninformatie EDB bij de ziekte van Ménière – Juni 2021

Proefpersoneninformatie

Ik verklaar dat ik deze proefpersoon volledig heb geïnformeerd over het genoemde onderzoek.

Wordt er tijdens het onderzoek informatie bekend die de toestemming van de proefpersoon kan beïnvloeden? Dan laat ik dit op tijd weten aan deze proefpersoon.

Naam onderzoeker (of diens vertegenwoordiger):.....

Handtekening:.....

Datum: __ / __ / __

<indien van toepassing>

Aanvullende informatie is gegeven door:

Naam:.....

Functie:.....

Handtekening:.....

Datum: __ / __ / __

De proefpersoon krijgt een volledige informatiebrief mee, samen met een getekende versie van het toestemmingsformulier.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

			Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	4
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	NA
7	data set		Registration Data Set	
8				
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	20
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	20
21	responsibilities:			
22	contributorship			
23				
24				
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	20
29	responsibilities:			
30	sponsor contact			
31	information			
32				
33				
34				
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	20
39	responsibilities:		design; collection, management, analysis, and	
40	sponsor and funder		interpretation of data; writing of the report; and the	
41			decision to submit the report for publication, including	
42			whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	20
53	responsibilities:		coordinating centre, steering committee, endpoint	
54	committees		adjudication committee, data management team, and	
55				
56				
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-7
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	7
Objectives	#7	Specific objectives or hypotheses	7
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	7
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	9

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	9-10
2			applicable, eligibility criteria for study centres and	
3			individuals who will perform the interventions (eg,	
4			surgeons, psychotherapists)	
5				
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10-11
12			replication, including how and when they will be	
13	description		administered	
14				
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	11
20			interventions for a given trial participant (eg, drug dose	
21	modifications		change in response to harms, participant request, or	
22			improving / worsening disease)	
23				
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention	15
30			protocols, and any procedures for monitoring adherence	
31	adherence		(eg, drug tablet return; laboratory tests)	
32				
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	11
37			permitted or prohibited during the trial	
38	concomitant care			
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	14-16
43			specific measurement variable (eg, systolic blood	
44			pressure), analysis metric (eg, change from baseline,	
45			final value, time to event), method of aggregation (eg,	
46			median, proportion), and time point for each outcome.	
47				
48				
49				
50				
51				
52				
53			Explanation of the clinical relevance of chosen efficacy	
54			and harm outcomes is strongly recommended	
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including any	Table 2
2			run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly	
4			recommended (see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	14-15
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any	
14			sample size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment	9
22			to reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	10
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document	
41			that is unavailable to those who enrol participants or	
42			assign interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	10
54	concealment		central telephone; sequentially numbered, opaque,	
55				
56				
57				
58				
59				
60				

sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Allocation: #16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 10

Blinding (masking) #17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 10

Blinding (masking): #17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial 12

Methods: Data collection, management, and analysis

Data collection plan #18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 15

1	Data collection plan:	#18b	Plans to promote participant retention and complete	15
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	15
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18				
19				
20				
21				
22				
23	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	16
24			outcomes. Reference to where other details of the	
25			statistical analysis plan can be found, if not in the	
26			protocol	
27				
28				
29				
30				
31				
32				
33	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	16
34	analyses		adjusted analyses)	
35				
36				
37				
38				
39	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	15
40	population and		adherence (eg, as randomised analysis), and any	
41	missing data		statistical methods to handle missing data (eg, multiple	
42			imputation)	
43				
44				
45				
46				
47				
48	Methods: Monitoring			
49				
50				
51	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	17
52	formal committee		summary of its role and reporting structure; statement of	
53			whether it is independent from the sponsor and	
54				
55				
56				
57				
58				
59				
60				

competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed

1			
2			
3			
4			
5			
6			
7			
8			
9			
10	Data monitoring:	#21b	Description of any interim analyses and stopping
11			
12	interim analysis		guidelines, including who will have access to these
13			
14			interim results and make the final decision to terminate
15			the trial
16			
17			
18			
19			
20	Harms	#22	Plans for collecting, assessing, reporting, and managing
21			
22			solicited and spontaneously reported adverse events and
23			
24			other unintended effects of trial interventions or trial
25			conduct
26			
27			
28			
29			
30	Auditing	#23	Frequency and procedures for auditing trial conduct, if
31			
32			any, and whether the process will be independent from
33			
34			investigators and the sponsor
35			
36			
37			
38	Ethics and		
39			
40	dissemination		
41			
42			
43	Research ethics	#24	Plans for seeking research ethics committee /
44			
45	approval		institutional review board (REC / IRB) approval
46			
47			
48	Protocol	#25	Plans for communicating important protocol modifications
49			
50	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to
51			relevant parties (eg, investigators, REC / IRBs, trial
52			participants, trial registries, journals, regulators)
53			
54			
55			
56			
57			
58			
59			
60			

1	Consent or assent	#26a	Who will obtain informed consent or assent from	9
2				
3			potential trial participants or authorised surrogates, and	
4				
5			how (see Item 32)	
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	NA
10				
11	ancillary studies		participant data and biological specimens in ancillary	
12				
13			studies, if applicable	
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	9
17				
18			participants will be collected, shared, and maintained in	
19				
20			order to protect confidentiality before, during, and after	
21				
22			the trial	
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	20
27				
28	interests		investigators for the overall trial and each study site	
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	15
33				
34			dataset, and disclosure of contractual agreements that	
35				
36			limit such access for investigators	
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	14
40				
41	trial care		compensation to those who suffer harm from trial	
42				
43			participation	
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	17
48				
49	trial results		results to participants, healthcare professionals, the	
50				
51			public, and other relevant groups (eg, via publication,	
52				
53			reporting in results databases, or other data sharing	
54				
55			arrangements), including any publication restrictions	
56				
57				
58				
59				
60				

1	Dissemination policy: #31b	Authorship eligibility guidelines and any intended use of	17-18
2			
3	authorship	professional writers	
4			
5			
6	Dissemination policy: #31c	Plans, if any, for granting public access to the full	17
7			
8	reproducible	protocol, participant-level dataset, and statistical code	
9			
10	research		
11			
12			
13			
14	Appendices		
15			
16			
17	Informed consent #32	Model consent form and other related documentation	Attached
18			
19	materials	given to participants and authorised surrogates	
20			
21			
22			
23	Biological specimens #33	Plans for collection, laboratory evaluation, and storage of	n/a
24			
25		biological specimens for genetic or molecular analysis in	
26			
27		the current trial and for future use in ancillary studies, if	
28			
29		applicable	
30			
31			

32 The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
 33 Commons Attribution License CC-BY-NC. This checklist was completed on 14. June 2021 using
 34 <https://www.goodreports.org/>, a tool made by the EQUATOR Network in collaboration with
 35 Penelope.ai
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60